Form 8-K

8-K — Annovis Bio, Inc.

Accession: 0001104659-26-041584

Filed: 2026-04-10

Period: 2026-04-09

CIK: 0001477845

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2611267d2_8k.htm (Primary)

EX-4.1 — EXHIBIT 4.1 (tm2611267d2_ex4-1.htm)

EX-5.1 — EXHIBIT 5.1 (tm2611267d2_ex5-1.htm)

EX-10.1 — EXHIBIT 10.1 (tm2611267d2_ex10-1.htm)

EX-99.1 — EXHIBIT 99.1 (tm2611267d2_ex99-1.htm)

GRAPHIC (tm2611267d2_ex5-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2611267d2_8k.htm · Sequence: 1

false

0001477845

2026-04-09

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date

of earliest event reported): April 9, 2026

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-39202

26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

101

Lindenwood Drive, Suite 225

Malvern, PA

19355

(Address of Principal Executive Offices, and

Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including

Area Code

Not

Applicable

(Former Name or Former Address, if Changed Since

Last Report)

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name

of each exchange on which

registered

Common Stock, par value $0.0001 per share

ANVS

New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company,

indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01

Entry into a Material Definitive Agreement.

Underwritten Registered Direct Offering

On April 9, 2026, Annovis Bio, Inc.

(the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of April 9,

2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell,

in an underwritten registered direct offering (the “Offering”) (i) an aggregate of 5,263,156 shares of common stock (the

“Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common

stock warrants to purchase an aggregate of 5,263,156 shares of Common Stock (the “Warrants” and the shares of Common Stock

issuable upon exercise of the Warrants, the “Warrant Shares”). The Warrants are exercisable beginning six months after their

issue date, expire five and one-half years from the date of issuance and have an exercise price equal to $2.50 per share of Common Stock.

The combined offering price of each Share and accompanying Warrant is $1.90 per share. The gross proceeds to the Company from the Offering

are expected to be approximately $10 million, before deducting offering expenses payable by the Company.

The Offering is expected to close on or about April 10, 2026,

subject to the satisfaction of customary closing conditions. The Company currently plans to use the net proceeds from the Offering, for

the continued clinical development of the Company’s lead compound Buntanetap in a Phase 3 study for Alzheimer’s disease, and

for working capital and general corporate purposes.

The Underwriting Agreement contains customary

representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company,

including for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of

the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made

only for the purposes of such agreement and as of the specific dates, were solely for the benefit of the parties to such agreement and

may be subject to limitations agreed upon by the contracting parties.

The Offering was made pursuant to the Company’s

effective shelf registration statement on Form S-3 (File No. 333-276814), which was declared effective on February 12,

2024, and a related base prospectus and prospectus supplement thereunder dated April 9, 2026.

The legal opinion of Loeb & Loeb LLP relating to the Shares, Warrants

and Warrant Shares is filed herewith as Exhibit 5.1.

The foregoing descriptions of the terms and conditions of the Undewriting

Agreementand the Warrant do not purport to be complete and are qualified in its entirety by the full text of each of such document, copies

of which are attached hereto as Exhibits 10.1 and 4.1, respectively, and incorporate by reference herein.

Item 7.01

Regulation FD Disclosure

On April 9, 2026, the Company issued a press release announcing

the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated

by reference herein.

The information contained in this Item 7.01 shall

not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific

reference in such a filing.

Item 9.01

Financial Statements and Exhibits

Exhibit Number

Description

4.1

Form of

Warrant

5.1

Opinion

of Loeb & Loeb LLP

10.1

Underwriting

Agreement

23.1

Consent

of Loeb & Loeb LLP (contained in Exhibit 5.1)

99.1

Press Release, dated April 9, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANNOVIS BIO, INC.

Date: April 9,

2026

By:

/s/ Maria Maccecchini

Name:

Maria Maccecchini

Title:

President and Chief Executive Officer

EX-4.1 — EXHIBIT 4.1

EX-4.1

Filename: tm2611267d2_ex4-1.htm · Sequence: 2

Exhibit 4.1

WARRANT TO PURCHASE COMMON STOCK

ANNOVIS BIO, INC.

Warrant Shares: [ ]

Issue Date: April 10, 2026

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”)

certifies that, for value received, [___] or its assigns (the “Holder”) is entitled, upon the terms and subject to

the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 10, 2026 (the “Initial

Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on that date that is five years and six months from

the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Annovis Bio, Inc.,

a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder,

the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. Capitalized

terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the “Underwriting

Agreement”), dated April 9, 2026, by and between the Company and Canaccord Genuity LLC.

Section 2. Exercise.

(a)            Exercise

of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on

or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed copy submitted

by email (or email attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within

one Trading Day following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares

specified in the applicable Notice of Exercise by wire transfer on a United States bank unless the cashless exercise procedure specified

in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required,

nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding

anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder

has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall

surrender this Warrant to the Company for cancellation within three Trading Days of the date on which the final Notice of Exercise is

delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares

available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal

to the applicable number of Warrant Shares so purchased. The Holder and the Company shall maintain records showing the number of Warrant

Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day

of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the

provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available

for purchase hereunder at any given time may be less than the amount stated on the face hereof.

(b)            Exercise

Price. The exercise price per share of Common Stock under this Warrant shall be $2.50, subject to adjustment hereunder (the “Exercise

Price”).

Exercise. If at the time of exercise hereof, there is no effective registration statement registering, or the prospectus contained

therein is not available for the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may also be exercised,

in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number

of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice

of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both

executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours”

(as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at

the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise

or (y) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”)

as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular

trading hours” on a Trading Day and is delivered within two hours thereafter (including until two hours after the close of “regular

trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable

Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered

pursuant to Section 2(a) hereof after two hours following the close of “regular trading hours” on such Trading Day;

(B) = the Exercise Price of this Warrant, as adjusted hereunder; and

(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if

such exercise were by means of a cash exercise rather than a cashless exercise.

If Warrant Shares are issued in such a cashless

exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares

shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to

this Section 2(c).

“Bid Price” means, for any

date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on

a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on

which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time)

to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed on a Trading Market and if the prices for the

Common Stock are then reported on the OTCQB Venture Market (“OTCQB”) or OTCQX Best Market (“OTCQX”),

as applicable, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as

applicable, (c) if the Common Stock is not then listed or quoted for trading on a Trading Market or on OTCQB or OTCQX and if prices

for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting

prices) (“The Pink Open Market”), the most recent bid price per share of the Common Stock so reported, or (d) in

all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by

the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses

of which shall be paid by the Company.

“VWAP” means, for any date,

the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading

Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market

on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City

time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of

the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then

listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar

organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,

or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in

good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees

and expenses of which shall be paid by the Company.

(d)            Mechanics

of Exercise.

i.            Delivery

of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares issued in connection with an exercise of the Warrant to

be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account

with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is

then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant

Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise

by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for

the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice

of Exercise by the date that is the earlier of (i) one Trading Day after the delivery to the Company of the Notice of Exercise and

(ii) one Trading Day after delivery of the aggregate Exercise Price to the Company (such date, the “Warrant Share Delivery

Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder

of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant

Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant

Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by

the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000

of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10

per Trading Day (increasing to $20 per Trading Day on the third Trading Day after such liquidated damages begin to accrue) for each Trading

Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees

to maintain a transfer agent (the “Transfer Agent”) that is a participant in the FAST program so long as this Warrant

remains outstanding and exercisable.

ii.            Delivery

of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and

upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing

the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects

be identical with this Warrant.

iii.            Rescission

Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by

the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by providing the Company with written notice

of recission.

iv.            Compensation

for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if

the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above

pursuant to an exercise on or before the Warrant Share Delivery Date (other than a failure that is solely due to any action or inaction

by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market

transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction

of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),

then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price

(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying

(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with such exercise by (2) the

price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate

the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise

shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely

complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase

price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrant Shares with an aggregate sale price giving rise to

such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay

the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the

Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue

any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or

injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as

required pursuant to the terms hereof.

v.            No

Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this

Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the number of Warrant

Shares to be issued shall be rounded down to the nearest whole number and the Company shall, at its election, either pay a cash adjustment

in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

vi.            Charges,

Taxes and Expenses. Issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax

or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,

and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,

however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when

surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company

may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company

shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company

(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

(e)            Holder’s

Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise

any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise

as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting

as a group together with the Holder or any of the Holder’s Affiliates and any other Persons whose beneficial ownership of the shares

of Common Stock would or could be aggregated with the Holder’s for the purposes of Section 13(d) of the Exchange Act (such

Persons, “Attribution Parties”)), would exceed the Beneficial Ownership Limitation (as defined below). For purposes

of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties

shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is

being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised

portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion

of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock

Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the

Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e),

beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations

promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is

in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed

in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether

this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)

and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise

shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by

the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject

to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination

(other than to the extent that the information on the number of outstanding shares of Common Stock is provided by the Company, either

directly or through one or more public filings relied upon by the Holder). In addition, a determination as to any group status as contemplated

above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated

thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely

on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report

filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written

notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request

of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock

then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion

or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date

as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall

be 4.99% (or, upon election by the Holder prior to the issuance of this Warrant, 9.99%) of the number of shares of the Common Stock outstanding

immediately after giving effect to the issuance of Warrant Shares issuable upon exercise of this Warrant. In the event the Holder holds

less than 20% of the number of shares of Common Stock outstanding prior to giving effect to the issuance of shares of Common Stock issuable

upon exercise of this Warrant, the Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions

of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 19.99% (or, upon the election by the

Holder prior to the issuance of this Warrant, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving

effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall

continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered

to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with

the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with

the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give

effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

Section 3. Certain Adjustments.

(a)            Stock

Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes

a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of

Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant),

(ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse

stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of

the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of

which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such

event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number

of Warrant Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this

Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the

record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately

after the effective date in the case of a subdivision, combination or re-classification.

(b)            Subsequent

Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues

or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all (or substantially

all) of the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be

entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired

if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations

on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is

taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders

of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,

that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial

Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership

of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held

in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership

Limitation).

Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution

of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,

without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,

corporate rearrangement, scheme of arrangement or other similar transaction) other than dividends or distributions subject to Section 3(a) above

(a “Distribution”), or other than a reclassification to which Section 3(d) applies, then at any time after

the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent

that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise

of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)

immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the

record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however,

that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial

Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership

of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance

for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership

Limitation).

(d)            Fundamental

Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related

transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (all of its subsidiaries,

taken as a whole) directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all

or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender

offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted

to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of

the outstanding Common Stock or 50% or more of the voting power of the outstanding common equity of the Company, (iv) the Company,

directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common

Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,

cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase

agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme

of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares

of Common Stock or 50% or more of the voting power of the outstanding common equity of the Company (each a “Fundamental Transaction”),

then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have

been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without

regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor

or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate

Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for

which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on

the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted

to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock

in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable

manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given

any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same

choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding

anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at

the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction

(or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by

paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this

Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction

is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled

to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), valued at the

Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company

in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or

whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the

Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration

in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which

Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value”

means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg

determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free

interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the

applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100

day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day

immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per

share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the

value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period

beginning on the Trading Day immediately preceding the public announcement of the applicable Fundamental Transaction (or the consummation

of the applicable contemplated Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant

to this Section 3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the

applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black

Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five

Business Days of the Holder’s election and (ii) the effective date of the Fundamental Transaction. The Company shall cause

any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”)

to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the

provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and

approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver

to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar

in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity

(or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard

to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the

exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant

to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise

price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental

Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,

the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions

of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity),

and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the

other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. For the avoidance of

doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of whether the Company

has sufficient authorized shares of Common Stock for the issuance of Warrant Shares.

(e)            Calculations.

All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For

purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be

the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

(f)            Notice

to Holder.

i.            Adjustment

to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly

deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number

of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii.            Notice

to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the

Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the

Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of

capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection

with a Fundamental Transaction, any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of

its subsidiaries) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange

whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or

involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered

by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days

prior to the applicable record or effective date hereinafter specified, a notice (unless such information is filed with the Commission,

in which case a notice shall not be required) stating (x) the date on which a record is to be taken for the purpose of such dividend,

distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock

of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on

which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the

date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock

for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;

provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the

corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,

material, non-public information regarding the Company or any of the subsidiaries, the Company shall simultaneously file such notice with

the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period

commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set

forth herein.

Section 4. Transfer of Warrant.

(a)            Transferability.

Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder are transferable, in whole or in part,

upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this

Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any

transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute

and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations

specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so

assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required

to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall

surrender this Warrant to the Company within three Trading Days of the date on which the Holder delivers an assignment form to the Company

assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase

of Warrant Shares without having a new Warrant issued.

(b)            New

Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,

together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or

its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,

the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance

with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with

this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant

Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder

of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other

purposes, absent actual notice to the contrary.

Section 5. Miscellaneous.

(a)            No

Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends

or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly

set forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant

to Section 2(c), or to receive cash payments contemplated by Section 2(d)(i) and Section 2(d)(iv) herein, in

no event will the Company be required to net cash settle an exercise of this Warrant.

(b)            Loss,

Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory

to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case

of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include

the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make

and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or

granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading

Day.

(d)            Authorized

Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued

Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of this Warrant. The Company

further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing

the necessary Warrant Shares upon the exercise of this Warrant. The Company will take all such reasonable action as may be necessary to

assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements

of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon

the exercise of this Warrant will, upon exercise hereunder and payment for such Warrant Shares in accordance herewith, be duly authorized,

validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue

thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented

to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through

any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action,

avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in

the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder

as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase

the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,

(ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and

nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations,

exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform

its obligations under this Warrant.

Before taking any action which would result in

an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain

all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having

jurisdiction thereof.

(e)            Jurisdiction.

All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance

with the provisions of the Underwriting Agreement.

(f)            Restrictions.

The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not

utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

(g)            Nonwaiver

and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as

a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this

Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which

results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs

and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the

Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

(h)            Notices.

Any and all notices or other communications or deliveries hereunder (including, without limitation, any Notice of Exercise) shall be in

writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication

is delivered via confirmed email prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date

of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30

P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized

overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is

required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:

If to the Company:

Annovis Bio, Inc.

101 Lindenwood Drive, Suite 225,

Malvern, PA 19355

Attention: Chief Executive Officer

Email: maccecchini@annovisbio.com

With copy to:

Loeb & Loeb LLP

345 Park Avenue,

New York, NY 10154

Attention: Joan Guilfoyle

Email: jguilfoyle@loeb.com

If to the Holder, to its address or e-mail address on the books and

records of the Company.

(i)            (i) Warrant

Agent. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days’ notice to the Holder,

the Company may appoint a new warrant agent; provided, that if the Company enters into a warrant agency agreement with any such

new warrant agent and the terms of any such warrant agency agreement conflicts with the terms of this Warrant, the terms of this Warrant

shall prevail. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation

to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers

substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without

any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first

class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

(j)            Limitation

of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant

Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase

price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the

Company.

(k)            Remedies.

The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific

performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss

incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any

action for specific performance that a remedy at law would be adequate.

(l)            Successors

and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the

benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.

The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable

by the Holder or holder of Warrant Shares.

(m)            Amendment.

This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and

the Holder of this Warrant, on the other hand.

(n)            Severability.

Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,

but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the

extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

(o)            Headings.

The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

**************************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this

Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

Annovis Bio, Inc.

By:

Name:

Title:

NOTICE OF EXERCISE

TO:          ANNOVIS

BIO, INC.

(1)            The

undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders

herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2)            Payment

shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] if permitted the cancellation of such number of Warrant

Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum

number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

(3)            Please

issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following

DWAC Account Number:

[SIGNATURE OF HOLDER]

Name

of Investing Entity:

Signature

of Authorized Signatory of Investing Entity:

Name

of Authorized Signatory:

Title

of Authorized Signatory:

Date:

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required

information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced

thereby are hereby assigned to

Name:

(Please Print)

Address:

(Please Print)

Phone Number:

Email Address:

Dated:

Holder’s Signature:

Holder’s Address:

EX-5.1 — EXHIBIT 5.1

EX-5.1

Filename: tm2611267d2_ex5-1.htm · Sequence: 3

Exhibit 5.1

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Main   212.407.4000

Fax      212.407.4990

April 9, 2026

Annovis Bio, Inc.

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

Ladies and Gentlemen:

We have acted as counsel to

Annovis Bio, Inc., a Delaware corporation (the “Company”), in connection with the offer and sale by the Company of (i)

an aggregate of 5,263,156 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common

Stock”), and (ii) accompanying common stock warrants, to purchase an aggregate of 5,263,156 shares of Common Stock (the “Warrants”

and the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”), in each case pursuant to that

certain Underwriting Agreement, by and between the Company and Canaccord Genuity LLC, as underwriter, dated April 9, 2026 (the “Underwriting

Agreement”). The Common Stock, Warrants and Warrant Shares are referred to herein as the “Securities.” The Securities

are being offered for sale pursuant to the Company’s registration statement on Form S-3, as amended (File No. 333-276814) (the

“Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “Commission”) under the

Securities Act of 1933, as amended (the “Securities Act”) and the rules and regulations promulgated thereunder, the base prospectus,

dated February 12, 2024 (the “Base Prospectus”), and the prospectus supplement, dated April 9, 2026, filed pursuant to Rule

424(b)(5) under the Securities Act (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”).

Terms not defined herein shall have the same meaning as in the Underwriting Agreement.

In connection with the

opinions set forth below, we have examined the Registration Statement, the General Disclosure Package, the Prospectus, the Underwriting

Agreement and the form of Warrant. We have also examined originals or copies, certified or otherwise identified to our satisfaction, of

the Company’s amended and restated certificate of incorporation and amended and restated bylaws, and such corporate records of the

Company and other certificates and documents of officials of the Company, public officials and others as we have deemed appropriate for

purposes of this letter. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals,

and the conformity to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies.

Based upon the foregoing and

subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that:

1. The Shares have been duly

authorized for issuance, and, when issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the

Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.

2. The Warrants have been

duly authorized for issuance and when executed and delivered in accordance with the terms and conditions of the Underwriting Agreement,

the Registration Statement and the Prospectus, will constitute valid and legally binding obligations of the Company, enforceable against

the Company in accordance with their terms.

3. The Warrant Shares have

been duly authorized for issuance and if, as, and when the Warrant Shares are issued and delivered by the Company upon exercise of the

Warrants in accordance with the terms thereof, including, without limitation, the payment in full of applicable consideration, will be

validly issued, fully paid and non-assessable

The opinions we express above

are based upon a review only of those laws, statutes, rules, ordinances and regulations which, in our experience, a securities lawyer

who is a member of the bar of the State of New York and practicing before the Commission exercising customary professional diligence would

reasonably recognize as being applicable to the foregoing transactions.

The opinions set forth in

paragraph 2 above are subject to (i) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar law relating

to or affecting creditors’ rights generally (including, without limitation, fraudulent conveyance laws) and (ii) the effect of general

principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible

unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding in equity or at law.

We express no opinion as to

the enforceability of (i) provisions that relate to choice of law, forum selection or submission to jurisdiction (including, without limitation,

any express or implied waiver of any objection to venue in any court or of any objection that a court is an inconvenient forum) to the

extent that the validity, binding effect or enforceability of any such provision is to be determined by any court other than a state court

of the State of New York and (ii) waivers by the Company of any statutory or constitutional rights or remedies. We draw your attention

to the fact that, under certain circumstances, the enforceability of terms to the effect that provisions may not be waived or modified

except in writing may be limited.

The opinions we express herein

are limited to matters involving the internal laws of the State of New York and the Delaware General Corporation law.

This opinion has been prepared

solely for use in connection with the transmitting for filing of the Prospectus Supplement on the date of this letter and may be relied

upon for no other purpose without our prior written consent.

We hereby consent to the filing

of this letter with the Commission as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issuance

and sale of the Shares, the Warrants and the Warrant Shares in accordance with the requirements of Item 601(b)(5) of Regulation S-K under

the Securities Act and to the reference to our firm therein and in the Prospectus under the caption “Legal Matters.” In giving

such consent, we do not thereby admit that this firm is within the category of persons whose consent is required under Section 7 of the

Securities Act or the rules and regulations of the Commission under such Section.

Very truly yours,

/s/ Loeb & Loeb LLP

Loeb & Loeb LLP

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2611267d2_ex10-1.htm · Sequence: 4

Exhibit 10.1

ANNOVIS BIO, INC.

5,263,156 Shares of Common Stock

Warrants to Purchase 5,263,156 Shares of Common

Stock

UNDERWRITING AGREEMENT

April 9, 2026

CANACCORD GENUITY LLC

Penn 1, One Pennsylvania Plaza, Suite 2900

New York, NY 10119

Dear Sirs and Madams:

1.             INTRODUCTORY.

Annovis Bio, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Underwriting

Agreement (this “Agreement”), to the underwriter named in Schedule A hereto (the “Underwriter”),

(i) an aggregate of 5,263,156 shares (the “Shares”) of common stock, $0.0001 par value per share (the “Common

Stock”), of the Company and (ii) accompanying Warrants, substantially in the form of Annex A hereto, to purchase

an aggregate of 5,263,156 shares of Common Stock with an exercise price equal to $2.50 per share (the “Accompanying Warrants”

and such Accompanying Warrants and Shares being hereinafter collectively referred to as the “Securities”). As used

herein, “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Accompanying Warrants.

2.             REPRESENTATIONS

AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Underwriter, as of the date hereof and as of the Closing Date

(as defined below), and agrees with the Underwriter, that:

(a)            Registration

Statement. A registration statement of the Company on Form S-3 (File No. 333-276814) (including all amendments thereto,

the “Initial Registration Statement”) in respect of the Securities has been filed with the Securities and Exchange

Commission (the “Commission”) pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities

Act”), and the rules and regulations of the Commission thereunder (the “Rules and Regulations”).

The Company represents and warrants that it meets the requirements for the use of Form S-3 set forth in General Instruction I.A of

Form S-3 and that the proposed offering of the Securities may be made pursuant to General Instruction I.B.1 of Form S-3. The

Initial Registration Statement and any post-effective amendment thereto, each in the form, excluding exhibits thereto, heretofore delivered

or made available to you, have been declared effective by the Commission in such form and meet the requirements of the Securities Act

and the Rules and Regulations. The Initial Registration Statement and any post-effective amendment thereto, each in the form excluding

exhibits heretofore delivered or made available to you have been declared effective by the Commission in such form and meet the requirements

of the Securities Act and the Rules and Regulations. Other than (i) the Initial Registration Statement, (ii) a registration

statement, if any, increasing the size of the offering filed pursuant to Rule 462(b) under the Securities Act and the Rules and

Regulations (a “Rule 462(b) Registration Statement”), (iii) any Preliminary Prospectus (as defined below),

(iv) the Prospectus (as defined below) contemplated by this Agreement to be filed pursuant to Rule 424(b) of the Rules and

Regulations in accordance with Section 4(a) hereof and (v) any Issuer Free Writing Prospectus (as defined below), no other

document with respect to the offer and sale of the Securities has heretofore been filed with the Commission. No stop order suspending

the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration

Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been initiated

or, to the Company’s knowledge, threatened by the Commission (any preliminary prospectus included in the Initial Registration Statement

or filed with the Commission pursuant to Rule 424 of the Rules and Regulations is hereinafter called a “Preliminary

Prospectus”). The Initial Registration Statement including all exhibits thereto and including the information contained in the

Prospectus filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations and deemed by virtue of Rule 430A,

Rule 430B and Rule 430C, as applicable, under the Securities Act to be part of the Initial Registration Statement at the time

it became effective is hereinafter collectively called the “Registration Statement.” If the Company has filed a Rule 462(b) Registration

Statement, then any reference herein to the term “Registration Statement” shall be deemed to include such Rule 462 Registration

Statement. The base prospectus included in the Initial Registration Statement at the time of effectiveness thereof (the “Base

Prospectus”), as supplemented by the final prospectus supplement relating to the offer and sale of the Securities, in the form

filed pursuant to and within the time limits described in Rule 424(b) under the Rules and Regulations, is hereinafter called

the “Prospectus.”

Any reference herein to the Registration Statement,

Base Prospectus, Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference

therein. Any reference to any amendment or supplement to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and

include any documents filed after the date of such Preliminary Prospectus or the Prospectus under the Securities Exchange Act of 1934,

as amended (the “Exchange Act”), and incorporated by reference in such Preliminary Prospectus or Prospectus, as the

case may be. Any reference to (i) the Registration Statement shall be deemed to refer to and include the annual report on Form 10-K

of the Company for the last completed fiscal year of the Company for which an annual report on Form 10-K has been filed under Section 13(a) or

15(d) of the Exchange Act prior to the date hereof and (ii) the effective date of such Registration Statement shall be deemed

to refer to and include the date such Registration Statement became effective and, if later, the date such Form 10-K was so filed.

Any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the Company

filed pursuant to Section 13(a) or 15(d) of the Exchange Act after the date of this Agreement that is incorporated by reference

in the Registration Statement.

(b)            General

Disclosure Package. As of the Applicable Time (as defined below) and as of the Closing Date, neither (i) the General Use Free

Writing Prospectus(es) (as defined below) issued at or prior to the Applicable Time, and the Pricing Prospectus (as defined below) and

the information included on Schedule C hereto, all considered together (collectively, the “General Disclosure Package”),

(ii) any individual Limited Use Free Writing Prospectus (as defined below), nor (iii) the bona fide electronic roadshow (as

defined in Rule 433(h)(5) of the Rules and Regulations), when considered together with the General Disclosure Package,

included or will include any untrue statement of a material fact or omitted or will omit to state a material fact necessary in order to

make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the

Company makes no representations or warranties as to information contained in or omitted from the Pricing Prospectus or any Issuer Free

Writing Prospectus (as defined below), in reliance upon, and in conformity with, written information furnished to the Company through

the Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriter’s Information

(as defined herein). As used in this paragraph (b) and elsewhere in this Agreement:

“Applicable Time”

means 8:00 A.M., New York time, on the date of this Agreement or such other time as agreed to by the Company and the Underwriter.

“Pricing Prospectus”

means the Base Prospectus, as amended and supplemented immediately prior to the Applicable Time, including any document incorporated

by reference therein and any prospectus supplement deemed to be a part thereof.

“Issuer Free Writing

Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the Rules and Regulations

relating to the Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form

retained in the Company’s records pursuant to Rule 433(g) of the Rules and Regulations.

“General Use Free

Writing Prospectus” means any Issuer Free Writing Prospectus that is identified on Schedule B to this Agreement.

“Limited Use Free

Writing Prospectuses” means any Issuer Free Writing Prospectus that is not a General Use Free Writing Prospectus.

“Written Testing-the-Waters

Communication” means any Testing-the-Waters Communication (as defined below) that is a written communication within the meaning

of Rule 405 of the Rules and Regulations.

Stop Orders; No Material Misstatements. No order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing

Prospectus or the Prospectus relating to the proposed offering of the Securities has been issued by the Commission, and no proceeding

for that purpose or pursuant to Section 8A of the Securities Act has been instituted or threatened by the Commission, and each Preliminary

Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Securities Act and the Rules and

Regulations, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein

or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however,

that the Company makes no representations or warranties as to information contained in or omitted from any Preliminary Prospectus, in

reliance upon, and in conformity with, written information furnished to the Company through the Underwriter specifically for inclusion

therein, which information the parties hereto agree is limited to the Underwriter’s Information.

(d)            Registration

Statement and Prospectus Contents. At the respective times the Registration Statement and any amendments thereto became or become

effective and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects

to the requirements of the Securities Act and the Rules and Regulations and did not and will not contain any untrue statement of

a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading;

and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued

and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and the Rules and

Regulations and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order

to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that the

foregoing representations and warranties in this paragraph (d) shall not apply to information contained in or omitted from the Registration

Statement or the Prospectus, or any amendment or supplement thereto, in reliance upon, and in conformity with, written information furnished

to the Company through the Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the

Underwriter’s Information.

(e)            Issuer

Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the completion

of the public offer and sale of the Securities or until any earlier date that the Company notified or notifies the Underwriter as described

in Section 4(f), did not, does not and will not include any information that conflicted, conflicts or will conflict with the information

contained in the Registration Statement, the Pricing Prospectus or the Prospectus, including any document incorporated by reference therein

and any prospectus supplement deemed to be a part thereof that has not been superseded or modified, or included or would include an untrue

statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in order to

make the statements therein, in the light of the circumstances under which they were made, not misleading provided, however,

that the foregoing representations and warranties in this paragraph (e) shall not apply to information contained in or omitted from

the Registration Statement, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, in reliance upon, and in

conformity with, written information furnished to the Company through the Underwriter specifically for inclusion therein, which information

the parties hereto agree is limited to the Underwriter’s Information.

(f)            Documents

Incorporated by Reference. The documents incorporated by reference in the Prospectus, when they became effective or were filed with

the Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or the Exchange Act,

as applicable, and the rules and regulations of the Commission thereunder and none of such documents contained any untrue statement

of a material fact or omitted to state any material fact required to be stated therein, or necessary to make the statements therein, in

the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference

in the Prospectus, when such documents are filed with Commission will conform in all material respects to the requirements of the Securities

Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and will not contain any untrue

statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,

in the light of the circumstances under which they were made, not misleading.

(g)           Distribution

of Offering Materials. The Company has not, directly or indirectly, distributed and will not distribute any offering material in connection

with the offering and sale of the Securities other than any Preliminary Prospectus, the Prospectus and other materials, if any, permitted

under the Securities Act and consistent with Section 4(c) below. The Company will file with the Commission all Issuer Free Writing

Prospectuses (other than a “road show” as described in Rule 433(d)(8) of the Rules and Regulations) in the

time and manner required under Rules 163(b)(2) and 433(d) of the Rules and Regulations.

(h)           Not

an Ineligible Issuer. At the time of filing the Initial Registration Statement, any Rule 462(b) Registration Statement and

any post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an “ineligible

issuer,” as defined in Rule 405 of the Rules and Regulations.

(i)            Testing

the Waters Communications. The Company (a) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters

Communications with the consent of the Underwriter with entities that are qualified institutional buyers within the meaning of Rule 144A

under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and

(b) has not authorized anyone to engage in Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters

Communications other than those listed on Schedule D hereto. “Testing-the-Waters Communication” means any oral

or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.

(j)            Underwriting

Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(k)           The

Securities. The Shares to be issued and sold by the Company to the Underwriter hereunder have been duly authorized and, when issued

and delivered by the Company against payment therefor as provided herein, will be validly issued, fully paid and non-assessable and will

conform to the descriptions thereof in the Registration Statement, the General Disclosure Package and the Prospectus; and the issuance

of the Shares is not subject to any preemptive or similar rights. The Accompanying Warrants have been duly authorized by the Company and,

when executed and delivered by the Company, will be valid and binding agreements of the Company, enforceable against the Company in accordance

with their respective terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or

other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The Warrant Shares

have been duly authorized and validly reserved for issuance upon exercise of the Accompanying Warrants in a number sufficient to meet

the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Accompanying Warrants in accordance

therewith against payment of the exercise price as provided therein, will be validly issued, fully paid and nonassessable, and the issuance

of the Warrant Shares is not subject to any preemptive or similar rights.

(l)            No

Material Adverse Change. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus,

subsequent to the respective dates as of which information is given in the Registration Statement, the General Disclosure Package and

the Prospectus: (i) there has been no material adverse change in the condition (financial or otherwise), assets, rights, operations,

business, management or prospects of the Company (any such change is called a “Material Adverse Change”) or any development

involving a prospective material adverse change, which, individually or in the aggregate, has had or would reasonably be expected to result

in a Material Adverse Change; (ii) the Company has not incurred any material liability or obligation, indirect, direct or contingent,

not in the ordinary course of business nor entered into any material transaction or agreement not in the ordinary course of business;

and (iii) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of capital stock

or repurchase or redemption by the Company of any class of capital stock.

(m)          Independent

Accountants. Ernst & Young LLP, who have certified certain financial statements (which term as used in this Agreement includes

the related notes thereto) of the Company filed with the Commission or incorporated or included, as applicable, by reference in the Registration

Statement, the General Disclosure Package and the Prospectus, is (i) an independent registered public accounting firm as required

by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”),

(ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation

S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been

suspended or revoked and, to the knowledge of the Company, who has not requested such registration to be withdrawn.

(n)           Preparation

of the Financial Statements. The consolidated financial statements of the Company, together with related notes and schedules as incorporated

by reference in the Registration Statement, the General Disclosure Package and the Prospectus, present fairly the financial position and

the results of operations and cash flows of the Company, at the indicated dates and for the indicated periods. Such financial statements

and related schedules have been prepared in accordance with U.S. generally accepted principles of accounting, consistently applied throughout

the periods involved, except as disclosed therein, and all adjustments necessary for a fair presentation of results for such periods have

been made. The summary financial and statistical data included or incorporated by reference in the Registration Statement, the General

Disclosure Package and the Prospectus present fairly the information shown therein and such data has been compiled on a basis consistent

with the financial statements presented therein and the books and records of the Company. The statistical, industry-related and market-related

data included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus are based

on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and the Company has obtained

the written consent to the use of such data from such sources to the extent required. The financial data set forth or incorporated by

reference in the Registration Statement, the General Disclosure Package and Prospectus fairly present the information shown therein and

such data has been compiled on a basis consistent with the financial statements presented therein and the books and records of the Company.

(o)           XBRL.

The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the

General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared

in accordance with the Commission’s rules and guidelines applicable thereto.

(p)           Incorporation

and Good Standing of the Company. The Company is a corporation duly incorporated and validly existing under the laws of the State

of Delaware and is in good standing under such laws. The Company has requisite corporate power to carry on its business as described in

the Prospectus. The Company is duly qualified to transact business and is in good standing in all jurisdictions in which the conduct of

its business requires such qualification; except where the failure to be so qualified or to be in good standing would not result in a

Material Adverse Change.

(q)           Subsidiaries.

The Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint

venture, limited liability company, association, or other business entity.

(r)            Capital

Stock Matters. The Common Stock conforms in all material respects to the description thereof contained in the Registration Statement,

the General Disclosure Package and the Prospectus. The form of certificates for the Common Stock conforms to the corporate law of the

jurisdiction of the Company’s incorporation. All of the issued and outstanding shares of Common Stock have been duly authorized

and validly issued, are fully paid and nonassessable and have been issued in compliance with federal and state securities laws. None of

the outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal or other similar rights

to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights

of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital

stock of the Company other than those disclosed in or in a document filed as an exhibit to or incorporated by reference into the Registration

Statement, the General Disclosure Package and the Prospectus.

(s)           Non-Contravention

of Existing Instruments; No Further Authorizations or Approvals Required. The Company is not (i) in breach or violation of its

certificate or bylaws, (ii) in breach of or in default (or, with the giving of notice or lapse of time or both, would be in default)

(“Default”) under any indenture, mortgage, loan or credit agreement, deed of trust, note, contract, franchise, lease

or other agreement, obligation, condition, covenant or instrument to which the Company is a party or by which it may be bound or to which

any of the property or assets of the Company is subject (each, an “Existing Instrument”), or (iii) in violation

of any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body,

arbitrator or other authority having jurisdiction over the Company or any of its properties,, except, with respect to clauses (ii) and

(iii) only, for such breaches, violations or Defaults that would not, individually or in the aggregate, result in a Material Adverse

Change. The Company’s execution, delivery and performance of this Agreement and the Accompanying Warrants, and consummation of the

transactions contemplated hereby or thereby or by the Registration Statement, the General Disclosure Package and the Prospectus (including

the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as described in the Prospectus under

the caption “Use of Proceeds”) (i) will not result in any breach or violation of the certificate of incorporation or

bylaws of the Company, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as

defined below) under, or result in the creation or imposition of any lien, charge, claim or encumbrance upon any property or assets of

the Company pursuant to, or require the consent of any other party to, any Existing Instrument, and (iii) will not result in any

violation of any statute, law, rule, regulation, judgment, order or decree applicable to the Company of any court, regulatory body, administrative

agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of its properties, except, with respect

to clauses (ii) and (iii) only, for such conflicts, breaches, Defaults, Debt Repayment Triggering Events or violations

that would not, individually or in the aggregate, result in a Material Adverse Change. As used herein, a “Debt Repayment Triggering

Event” means any event or condition which gives, or with the giving of notice or lapse of time or both would give, the holder

of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf), issued by the Company,

the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company. Each approval, consent,

order, authorization, designation, declaration or filing by or with any regulatory, administrative or other governmental body necessary

in connection with the execution and delivery by the Company of this Agreement and the Accompanying Warrants, and the performance of the

Company of the transactions herein or therein contemplated has been obtained or made and is in full force and effect, except such additional

steps as may be required by the bylaws and rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”)

or the New York Stock Exchange (the “Exchange”) in connection with the purchase and distribution of the Securities

by the Underwriter and the listing of the Shares and the Warrant Shares on the Exchange.

(t)            No

Material Actions or Proceedings; Labor Disputes. There is no action, suit, claim or proceeding pending or, to the knowledge of the

Company, threatened against the Company before any court or administrative agency or otherwise (i) that is required to be described

in the Registration Statement, the General Disclosure Package or the Prospectus and are not so described or (ii) which, if determined

adversely to the Company, would reasonably be expected to result in a Material Adverse Change or prevent the consummation of the transactions

contemplated hereby, except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus. The aggregate

of all pending legal or governmental proceedings to which the Company is a party or of which any of its property or assets is the subject

which are not described in the Prospectus, including ordinary routine litigation incidental to the business, could not reasonably be expected

to result in a Material Adverse Change. No labor dispute with the employees of the Company exists or, to the Company’s knowledge,

is threatened or imminent, and the Company is not aware of any existing or imminent labor dispute by the employees of any of its principal

suppliers, contractors or customers, that would, individually or in the aggregate, reasonably be expected to result in a Material Adverse

Change. None of the employees of the Company is represented by a union and, to the knowledge of the Company, no union organizing activities

are taking place. The Company has not violated any federal, state or local law or foreign law relating to the discrimination in hiring,

promotion or pay of employees, nor any applicable wage or hour laws, or the rules and regulations thereunder, or analogous foreign

laws and regulations, which might, individually or in the aggregate, result in a Material Adverse Change.

(u)           All

Necessary Permits, etc. The Company has all material licenses, certifications, permits, franchises, approvals, clearances and

other regulatory authorizations (“Permits”) from governmental authorities as are necessary to (i) conduct its

business as currently conducted and (ii) own, lease and operate its properties in the manner described in the Registration Statement,

the General Disclosure Package and the Prospectus. There is no claim or proceeding pending or, to the knowledge of the Company, threatened,

involving the status of or sanctions under any of the Permits. The Company has fulfilled and performed all of its material obligations

with respect to the Permits, and the Company is not aware of the occurrence of any event which allows, or after notice or lapse of time

would allow, the revocation, termination, or other impairment of the rights of the Company under such Permit.

(v)           Tax

Law Compliance. All United States federal income tax returns of the Company required by law to be filed have been filed or extensions

thereof have been requested, and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except

assessments that are being contested in good faith and as to which adequate reserves have been provided. The Company has filed all other

tax returns that are required to have been filed by it pursuant to applicable foreign, state, provincial, local or other law except insofar

as the failure to file such returns would not result in a Material Adverse Change, and has paid all taxes due pursuant to such returns

or pursuant to any assessment received by the Company, except for such taxes, if any, as are being contested in good faith and as to which

adequate reserves have been provided and except for such taxes or assessments the nonpayment of which would not, individually or in the

aggregate, result in a Material Adverse Change. The charges, accruals and reserves on the books of the Companyin respect of any income

and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments for additional

tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Change. All

material taxes which the Company is required by law to withhold or to collect for payment have been duly withheld and collected and have

been paid to the appropriate governmental authority or agency or have been accrued, reserved against and entered on the books of the Company.

There are no transfer taxes or other similar fees or charges under Federal law or the laws of any state, or any political subdivision

thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by the Company or sale of

the Securities.

(w)          Company

Not an “Investment Company”. The Company is not, and will not be, either after receipt of payment for the Securities or

after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement, the General

Disclosure Package or the Prospectus, required to register as an “investment company” under the Investment Company Act of

1940, as amended.

(x)            Insurance.

Except as otherwise described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company carries, or

is covered by, insurance in such amounts and covering such risks as is generally considered adequate for the conduct of its business and

the value of its properties and as is customary for companies engaged in similar industries. All policies of insurance insuring the Company

or its business, assets, employees, officers and directors are in full force and effect, and the Company is in compliance with the terms

of such policies in all material respects. There are no claims by the Company under any such policy or instrument as to which an insurance

company is denying liability or defending under a reservation of rights clause. The Company has no reason to believe that it will not

be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage

from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result

in a Material Adverse Change.

(y)           No

Price Stabilization or Manipulation. Neither the Company, nor any of its directors, officers or, to the knowledge of the Company,

controlling persons has taken, directly or indirectly, any action designed to or that might reasonably be expected to cause or result

in the stabilization or manipulation of the price of the Common Stock or of any “reference security” (as defined in Rule 100

of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Common Stock, whether to facilitate the

sale or resale of the Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation M.

(z)            Related

Party Transactions. There are no business relationships or related-party transactions involving the Company required to be described

in the Registration Statement, the General Disclosure Package or the Prospectus which have not been described (or described in documents

incorporated by reference therein) as required.

(aa)         Exchange

Act Compliance. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure

Package, the Prospectus or any amendment or supplement thereto, at the time they were or hereafter are filed with the Commission under

the Exchange Act, complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together

with the other information in the Registration Statement, the General Disclosure Package and the Prospectus, will not contain an untrue

statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to

be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(bb)         Compliance

with Environmental Laws. To its knowledge, the Company is not in violation of any statute, any rule, regulation, decision or order

of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous chemicals,

toxic substances or radioactive and biological materials or relating to the protection or restoration of the environment or human exposure

to hazardous chemicals, toxic substances or radioactive and biological materials (collectively, “Environmental Laws”).

The Company neither owns nor, to its knowledge, operates any real property contaminated with any substance that is subject to any Environmental

Laws, is not liable for any off-site disposal or contamination pursuant to any Environmental Laws, nor is it subject to any claim relating

to any Environmental Laws, which violation, contamination, liability or claim would individually or in the aggregate result in a Material

Adverse Change; and the Company is not aware of any pending investigation which might lead to such a claim.

(cc)         Intellectual

Property. To the Company’s knowledge, except as otherwise disclosed in the Registration Statement, the General Disclosure Package

and the Prospectus, the Company owns, or has obtained valid and enforceable licenses for, the patent applications, patents, trademarks,

trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the General

Disclosure Package and the Prospectus as being owned or licensed by them (collectively, “Intellectual Property”). To

the Company’s knowledge, except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus,

the conduct of its businesses in the manner described in the Registration Statement and the Prospectus does not and will not infringe

or misappropriate rights of a third party, except any such infringement or misappropriation as would not, individually or in the aggregate,

result in a Material Adverse Change. To the Company’s knowledge, the Intellectual Property owned by the Company has not been adjudged

by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company’s knowledge, except as

otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus: (i) there are no third parties

who have rights to any Intellectual Property, except for rights of third-party licensors with respect to Intellectual Property that are

disclosed in the Registration Statement, the General Disclosure Package and the Prospectus as licensed to the Company; and (ii) there

is no infringement by third parties of any Intellectual Property except any such infringement as would not, individually or in the aggregate,

result in a Material Adverse Change. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the

Prospectus, there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging

the Company’s rights in or to any Intellectual Property; (B) challenging the validity, enforceability or scope of any Intellectual

Property; or (C) asserting that the Company infringes or otherwise violates, or would, upon the commercialization of any product

or service described in the Registration Statement, the General Disclosure Package or the Prospectus as under development, infringe or

violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary intellectual property rights of

others, except in each case (A), (B), and (C), any such action, suit, proceeding or claim would not, individually or in the aggregate,

result in a Material Adverse Change. To the Company’s knowledge, except as otherwise disclosed in the Registration Statement, the

General Disclosure Package and the Prospectus, the Company has complied with the material terms of each agreement pursuant to which Intellectual

Property has been licensed to the Company, and all such agreements are in full force and effect, except to the extent anything inconsistent

with the foregoing would not, individually or in the aggregate, result in a Material Adverse Change. To the Company’s knowledge,

except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there are no material

defects in any of the patents or patent applications included in the Intellectual Property. To the Company’s knowledge, except as

otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company has taken all reasonable

steps to protect, maintain and safeguard its Intellectual Property, including the execution of appropriate nondisclosure, confidentiality

agreements and invention assignment agreements and invention assignments with their employees, and no employee of the Company is in or

has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, nondisclosure

agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to the Company Intellectual

Property and such employee’s employment with the Company, except anything inconsistent with the foregoing that would not, individually

or in the aggregate, result in a Material Adverse Change. To the Company’s knowledge, except as otherwise disclosed in the Registration

Statement, the General Disclosure Package and the Prospectus, the Company’s patent counsel has complied or is in the process of

complying with its duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of

the United States patents and patent applications included in the Company owned Intellectual Property. To the Company’s knowledge,

except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, none of the Company owned

Intellectual Property employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation

binding on the Company or any of its officers, directors or employees or otherwise in violation of the rights of any persons, except anything

inconsistent with the foregoing that would not, individually or in the aggregate, result in a Material Adverse Change.

(dd)         Brokers.

Other than the Underwriter, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder’s

fee or other fee or commission as a result of any transactions contemplated by this Agreement.

(ee)         No

Outstanding Loans or Other Indebtedness. There are no outstanding loans, advances (except normal advances for business expenses in

the ordinary course of business) or guarantees of indebtedness by the Company to or for the benefit of any of the officers or directors

of the Company or any of their respective family members, except as disclosed in the Registration Statement, the General Disclosure Package

and the Prospectus. The Company has not directly or indirectly extended or maintained credit, arranged for the extension of credit, or

renewed an extension of credit, in the form of a personal loan to or for any director or executive officer of the Company.

(ff)           No

Reliance. The Company has not relied upon the Underwriter or legal counsel for the Underwriter for any legal, tax or accounting advice

in connection with the offering and sale of the Securities.

(gg)         Broker-Dealer

Status. Neither the Company nor any of its related entities (i) is required to register as a “broker” or “dealer”

in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls

or is a “person associated with a member” or “associated person of a member” (within the meaning of Article I

of the NASD Manual administered by FINRA). To the Company’s knowledge, there are no affiliations or associations between any member

of FINRA and any of the Company’s officers, directors or 10% or greater security holders, except as set forth in the Registration

Statement, the General Disclosure Package and the Prospectus. All of the information (including, but not limited to, information regarding

affiliations, security ownership and trading activity) provided to the Underwriter or its counsel by the Company, its officers and directors

and the holders of any securities (debt or equity) or warrants, options or rights to acquire any securities of the Company in connection

with the filing to be made and other supplemental information to be provided to FINRA pursuant to Rule 5110 of FINRA in connection

with the transactions contemplated by this Agreement is true, complete and correct, and copies of any Company filings required to

be filed with FINRA have been filed with the Commission or delivered to the Underwriter for filing with FINRA.

(hh)         Compliance

with Laws. The Company has not been advised, and has no reason to believe, that it is not conducting business in compliance with all

applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure to be so in

compliance would not result in a Material Adverse Change. The Company maintains and periodically reviews written policies and procedures

reasonably designed to keep the Company and its employees conduct in connection with the Company’s business in compliance with all

applicable laws, rules and regulations of the jurisdictions in which it is conducting business.

(ii)           Certain

Regulations. The studies, tests and clinical trials conducted by or on behalf of the Company and its subsidiaries were and, if still

pending, are being conducted in compliance with experimental protocols, procedures and controls pursuant to accepted professional scientific

standards and all applicable laws and authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and

regulations promulgated thereunder, except where the failure to be in compliance could not reasonably be expected to result in a Material

Adverse Change; the descriptions of the results of such studies, tests and clinical trials contained in the Registration Statement, the

General Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the data derived from

such studies, tests and clinical trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package

and the Prospectus, to the knowledge of the Company, there are no studies, tests or clinical trials, the results of which the Company

believes reasonably call into question the study, test, or clinical trial results described or referred to in the Registration Statement,

the General Disclosure Package and the Prospectus when viewed in the context in which such results are described; and, except to the extent

disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company has not received any notices or

correspondence from any applicable governmental authority requiring the termination, suspension or material modification of any studies,

tests or clinical trials conducted by or on behalf of the Company.

(jj)           FDA

Regulations. The Company: (i) is and at all times has been in compliance with all statutes, rules, or regulations, including

but not limited to those administered by the United States Food and Drug Administration (“FDA”), the European Medicines

Agency (“EMA”) and similar governmental authorities applicable to the ownership, testing, development, manufacture,

packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of

any products being developed, manufactured or distributed by the Company (“Applicable Laws”), except as could not,

individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (ii) has not received any warning

letter or other correspondence or notice from the FDA, EMA or any other governmental authority alleging or asserting noncompliance with

any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto

required by any such Applicable Laws (“Authorizations”); (iii) possess all material Authorizations and such Authorizations

are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (iv) have not received

notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental

authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and

have no knowledge that any such governmental authority or third party is considering any such claim, litigation, arbitration, action,

suit, investigation or proceeding; (v) have not received notice that any governmental authority has taken, is taking or intends to

take action to limit, suspend, modify or revoke any Authorizations and have no knowledge that any such governmental authority is considering

such action; (vi) have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records,

claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents,

forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or

were corrected or supplemented by a subsequent submission); and (vii) have not, either voluntarily or involuntarily, initiated, conducted,

or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, or other notice

or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s

knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.

(kk)         Sarbanes–Oxley

Act. There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities

as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations

promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.

(ll)           Disclosure

Controls and Procedures. The Company has established and maintains “disclosure controls and procedures” (as defined in

Rules 13a–15(e) and 15d–15(e) of the Exchange Act); the Company’s “disclosure controls and procedures”

are reasonably designed to ensure that all information (both financial and non–financial) required to be disclosed by the Company

in the reports that it will file or furnish under the Exchange Act is recorded, processed, summarized and reported within the time periods

specified in the rules and regulations of the Commission, and that all such information is accumulated and communicated to the Company’s

management as appropriate to allow timely decisions regarding required disclosure and to make the certifications of the Chief Executive

Officer and Chief Financial Officer of the Company required under the Exchange Act with respect to such reports.

(mm)      Company’s

Accounting System. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that

(i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are

recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to

maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific

authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate

action is taken with respect to any differences.

(nn)         ERISA.

The Company is in compliance in all material respects with all presently applicable provisions of the Employee Retirement Income Security

Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”); no “reportable

event” (as defined in ERISA) has occurred with respect to any “pension plan” (as defined in ERISA) for which the Company

would have any liability; the Company has not incurred and does not expect to incur liability under (i) Title IV of ERISA with respect

to termination of, or withdrawal from, any “pension plan” or (ii) Sections 412 or 4971 of the Internal Revenue Code

of 1986, as amended, including the regulations and published interpretations thereunder (the “Code”); and each “pension

plan” for which the Company would have any liability that is intended to be qualified under Section 401(a) of the Code

is so qualified in all material respects and nothing has occurred, whether by action or by failure to act, which would cause the loss

of such qualification.

(oo)         Contracts

and Agreements. There are no contracts, agreements, instruments or other documents that are required to be described in the Registration

Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits thereto which have not been so described in all

material respects and filed as required by Item 601(b) of Regulation S-K under the Securities Act. The copies of all contracts, agreements,

instruments and other documents (including governmental licenses, authorizations, permits, consents and approvals and all amendments or

waivers relating to any of the foregoing) that have been furnished to the Underwriter or its counsel are complete and genuine and include

all material collateral and supplemental agreements thereto. All contracts and agreements between the Company and third parties expressly

referenced in the Registration Statement, the General Disclosure Package or the Prospectus are legal, valid and binding obligations of

the Company, enforceable against the Company in accordance with their respective terms, except as rights to indemnity thereunder (as applicable)

may be limited by federal or state securities laws and except as such enforceability may be limited by bankruptcy, insolvency, reorganization

or similar laws affecting the rights of creditors generally, and subject to general principles of equity.

(pp)         Title

to Properties. Except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, the Company has

good and marketable title to all of the properties and assets reflected as owned in the financial statements referred to in Section 6(j) above

(or elsewhere in the Registration Statement, the General Disclosure Package and the Prospectus), in each case free and clear of any security

interests, mortgages, liens, encumbrances, equities, claims and other defects, except such as do not materially and adversely affect the

value of such property or assets and do not materially interfere with the use made or proposed to be made of such property by the Company.

The material real property, improvements, equipment and personal property held under lease by the Company are held under valid and enforceable

leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real

property, improvements, equipment or personal property by the Company. The Company has such consents, easements, rights-of-way or licenses

from any person (“rights-of-way”) as are necessary to enable the Company to conduct its business in the manner described

in the Registration Statement, the General Disclosure Package and the Prospectus, and except for such rights-of-way the lack of which

would not, individually or in the aggregate, result in a Material Adverse Change.

(qq)         No

Unlawful Contributions or Other Payments. No payments or inducements have been made or given, directly or indirectly, to any federal

or local official or candidate for, any federal or state office in the United States or foreign offices by the Company or any of its officers

or directors, or, to the knowledge of the Company, by any of its employees or agents or any other person in connection with any opportunity,

contract, permit, certificate, consent, order, approval, waiver or other authorization relating to the business of the Company, except

for such payments or inducements as were lawful under applicable laws, rules and regulations. Neither the Company, nor, to the knowledge

of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the Company, (i) has

used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity;

(ii) made any direct or indirect unlawful payment to any government official or employee from corporate funds; or (iii) made

any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment in connection with the business of the Company.

(rr)           Foreign

Corrupt Practices Act. None of the Company or, to the knowledge of the Company, any director, officer, agent, employee, affiliate

or other person acting on behalf of the Company, is aware of or has taken any action, directly or indirectly, that would result in a violation

by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively,

the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce

corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise

to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA)

or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA. The Company

has conducted its business in compliance with the FCPA and has instituted and maintain policies and procedures designed to ensure, and

which are reasonably expected to continue to ensure, continued compliance therewith.

(ss)         Money

Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping

and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of

all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered

or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding

by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering

Laws is pending or, to the knowledge of the Company, threatened.

(tt)           OFAC.

None of the Company or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or person acting on behalf

of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department

(“OFAC”) or the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty’s

Treasury of the United Kingdom, or other relevant sanctions authority (collectively, “Sanctions”); and the Company

will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any

subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject

to any U.S. sanctions administered by OFAC; nor is the Company located, organized or resident in a country or territory that is the subject

or the target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria; and the Company will not directly

or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any

joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any

country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result

in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise)

of applicable Sanctions. For the past five years, the Company has not knowingly engaged in and are not now knowingly engaged in any dealings

or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with

any Sanctioned country.

(uu)         Exchange

Listing. The Common Stock is currently listed on the Exchange under the trading symbol “ANVS”. Except as disclosed in

the Registration Statement, the General Disclosure Package and the Prospectus, the Company has not, in the twelve (12) months preceding

the date of this Agreement, received notice from the Exchange to the effect that the Company is not in compliance with the listing or

maintenance requirements. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company

has no reason to believe that it will not in the foreseeable future continue to be in compliance with all such listing and maintenance

requirements.

(vv)         No

Material Defaults. The Company has not defaulted on any installment on indebtedness for borrowed money or on any rental on one or

more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected to result in a Material Adverse

Change.

(ww)       Cybersecurity.

Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus or would not, individually

or in the aggregate, reasonably be expected to result in a Material Adverse Change, the Company’s information technology assets

and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”)

are adequate for, and operate and perform as required in connection with the operation of the business of the Company as currently conducted,

free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company has implemented

and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain

and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems

and data, including “Personal Data,” used in connection with their businesses. “Personal Data” means (i) a

natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification

number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any

information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended;

(iii) “personal data” as defined by GDPR; (iv) any information which would qualify as “protected health information”

under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and

Clinical Health Act (collectively, “HIPAA”); and (v) any other piece of information that allows the identification

of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s

health or sexual orientation. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus,

there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied

without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating

to the same.

(xx)          Compliance

with Privacy Data. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus,

the Company is in material compliance with applicable state, federal and foreign data privacy and security laws and regulations, including,

to the extent applicable, the Health Insurance Portability and Accountability Act of 1996, as amended (collectively, “HIPAA”),

and the European Union General Data Protection Regulation (EU 2016/679) (collectively, the “Privacy Laws”). To the

extent required by the Privacy Laws, the Company has in place, complies in all material respects with, and takes commercially reasonable

steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and

security and the collection, storage, use, disclosure, and handling of Personal Data (the “Policies”). The Company

has made all disclosures to users or customers required by the Privacy Laws, and none of such disclosures made or contained in any Policy

have, to the knowledge of the Company, been inaccurate or in violation of any Privacy Laws. Except as otherwise disclosed in the Registration

Statement and the Prospectus, the Company has not: (i) has received written notice of any actual or potential liability under or

relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably

be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation,

or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation

or liability by any governmental or regulatory authority under any Privacy Law.

(yy)         No

Rated Securities. The Company does not have any securities rated by any “nationally recognized statistical rating organization,”

as such term is defined in Section 3(a)(62) of the Exchange Act.

Any certificate signed by

or on behalf of the Company and delivered to the Underwriter or to counsel for the Underwriter shall be deemed to be a representation

and warranty by the Company to such Underwriter as to the matters covered thereby.

3.            PURCHASE,

SALE AND DELIVERY OF OFFERED SECURITIES. On the basis of the representations, warranties and agreements herein contained, but subject

to the terms and conditions herein set forth, the Company agrees to sell to the Underwriter, and the Underwriter agrees to purchase from

the Company the number of Shares and Accompanying Warrants set forth opposite the name of the Underwriter in Schedule A hereto.

The purchase price to be paid

by the Underwriter to the Company for the Securities will be $1.7765 per Share and Accompanying Warrant (the “Purchase Price”).

The Company will deliver (a) the

Shares to the Underwriter through the facilities of The Depository Trust Company and (b) the Accompanying Warrants in physical certificated

form at the direction of the Underwriter, issued in such names and in such denominations as the Underwriter may direct by notice in writing

to the Company given at or prior to 12:00 Noon, New York time, on the first (1st) full business day preceding the Closing Date

against payment of the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an account at a bank specified

by the Company payable to the order of the Company at the offices of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., 919 Third

Avenue, New York, NY 10022. Time shall be of the essence, and delivery at the time and place specified pursuant to this Agreement is a

further condition of the obligations of Underwriter hereunder. The time and date of the delivery and closing shall be at 10:00 A.M., New

York time, on April 10, 2026, in accordance with Rule 15c6-1 of the Exchange Act. The time and date of such payment and delivery

are herein referred to as the “Closing Date”. The Closing Date and the location of delivery of, and the form of payment

for, the Securities may be varied by agreement among the Company and the Underwriter.

The Underwriter proposes to

offer the Securities for sale upon the terms and conditions set forth in the Prospectus.

4.             FURTHER

AGREEMENTS OF THE COMPANY. The Company agrees with the Underwriter:

(a)            Required

Filings; Amendments or Supplements; Notice to the Underwriter. To prepare the Rule 462(b) Registration Statement, if necessary,

in a form approved by the Underwriter and file such Rule 462(b) Registration Statement with the Commission by 10:00 P.M., New

York time, on the date hereof, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration

Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Rules and Regulations;

to prepare the Prospectus in a form approved by the Underwriter containing information previously omitted at the time of effectiveness

of the Registration Statement in reliance on Rule 403A, Rule 430B and Rule 430C of the Rules and Regulations and to

file such Prospectus pursuant to Rule 424(b) of the Rules and Regulations not later than the first (1st) business

day following the execution and delivery of this Agreement or, if applicable, such earlier time as may be required by the Securities Act;

to notify the Underwriter immediately of the Company’s intention to file or prepare any supplement or amendment to the Registration

Statement or to the Prospectus and to make no amendment or supplement to the Registration Statement, the General Disclosure Package or

to the Prospectus to which the Underwriter shall reasonably object by notice to the Company after a reasonable period to review; to advise

the Underwriter, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed

or becomes effective or any supplement to the General Disclosure Package or the Prospectus or any amended Prospectus or any Issuer Free

Writing Prospectus has been filed and to furnish the Underwriter with copies thereof; to file promptly all material required to be filed

by the Company with the Commission pursuant to Rules 433(d) or 163(b)(2) of the Rules and Regulations, as the case

may be; to file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission

pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as

the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) is

required in connection with the offering or sale of the Securities; to advise the Underwriter, promptly after it receives notice thereof,

of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus, any

Issuer Free Writing Prospectus or the Prospectus, of the suspension of the qualification of the Securities for offering or sale in any

jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request by the Commission for the amending

or supplementing of the Registration Statement, the General Disclosure Package or the Prospectus or for additional information; and, in

the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer

Free Writing Prospectus or the Prospectus or suspending any such qualification, and promptly to use its best efforts to obtain the withdrawal

of such order.

(b)            [Reserved.]

Free Writing Prospectus. The Company represents and agrees that, unless it obtains the prior consent of the Underwriter, and the Underwriter

represents and agrees that, unless it obtains the prior consent of the Company, it has not made and will not make any offer relating to

the Securities that would constitute a “free writing prospectus” as defined in Rule 405 of the Rules and Regulations

(each, a “Permitted Free Writing Prospectus”); provided that the prior written consent of the Underwriter hereto shall

be deemed to have been given in respect of the Issuer Free Writing Prospectuses included in Schedule B hereto. The Company represents

that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply

with the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free Writing Prospectus, including

the requirements relating to timely filing with the Commission, legending and record keeping and will not take any action that would result

in the Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) of the Rules and Regulations

a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to

file thereunder.

(d)            Ongoing

Compliance. If at any time prior to the date when a prospectus relating to the Securities is required to be delivered (or in lieu

thereof, the notice referred to in Rule 173(a) under the Securities Act) any event occurs or condition exists as a result of

which the Prospectus as then amended or supplemented would include any untrue statement of a material fact, or omit to state any material

fact necessary to make the statements therein, in light of the circumstances under which they were made when the Prospectus is delivered

(or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations), not misleading, or if it is necessary

at any time to amend or supplement the Registration Statement or the Prospectus or to file under the Exchange Act any document incorporated

by reference in the Prospectus to comply with the Securities Act or the Exchange Act, that the Company will promptly notify the Underwriter

thereof and upon its request will prepare an appropriate amendment or supplement or upon their request make an appropriate filing pursuant

to Section 13 or 14 of the Exchange Act in form and substance satisfactory to the Underwriter which will correct such statement or

omission or effect such compliance and will use its reasonable best efforts to have any amendment to the Registration Statement declared

effective as soon as possible. The Company will furnish without charge to the Underwriter and to any dealer in securities as many copies

as the Underwriter may from time to time reasonably request of such amendment or supplement. In case the Underwriter is required to deliver

a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) relating to the Securities,

the Company upon the request of the Underwriter will prepare promptly an amended or supplemented Prospectus as may be necessary to permit

compliance with the requirements of Section 10(a)(3) of the Securities Act and deliver to such Underwriter as many copies as

such Underwriter may request of such amended or supplemented Prospectus complying with Section 10(a)(3) of the Securities Act.

(e)            Amendment

to General Disclosure Package. If the General Disclosure Package is being used to solicit offers to buy the Securities at a time when

the Prospectus is not yet available to prospective purchasers and any event shall occur as a result of which, in the judgment of the Company

or in the reasonable opinion of the Underwriter, it becomes necessary to amend or supplement the General Disclosure Package in order to

make the statements therein, in the light of the circumstances then prevailing, not misleading, or to make the statements therein not

conflict with the information contained or incorporated by reference in the Registration Statement then on file and not superseded or

modified, or if it is necessary at any time to amend or supplement the General Disclosure Package to comply with any law, the Company

promptly will either (i) prepare, file with the Commission (if required) and furnish to the Underwriter and any dealers an appropriate

amendment or supplement to the General Disclosure Package or (ii) prepare and file with the Commission an appropriate filing under

the Exchange Act which shall be incorporated by reference in the General Disclosure Package so that the General Disclosure Package as

so amended or supplemented will not, in the light of the circumstances then prevailing, be misleading or conflict with the Registration

Statement then on file, or so that the General Disclosure Package will comply with law.

(f)             Amendment

to Issuer Free Writing Prospectus. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs

an event or development as a result of which such Issuer Free Writing Prospectus conflicted or will conflict with the information contained

in the Registration Statement, Pricing Prospectus or Prospectus, including any document incorporated by reference therein and any prospectus

supplement deemed to be a part thereof and not superseded or modified or included or would include an untrue statement of a material fact

or omitted or would omit to state a material fact required to be stated therein or necessary in order to make the statements therein,

in the light of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly notified or will promptly

notify the Underwriter so that any use of the Issuer Free Writing Prospectus may cease until it is amended or supplemented and has promptly

amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict,

untrue statement or omission. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus

in reliance upon, and in conformity with, written information furnished to the Company through the Underwriter specifically for inclusion

therein, which information the parties hereto agree is limited to the Underwriter’s Information.

(g)            Delivery

of Registration Statement. To the extent not available on the Commission’s Electronic Data Gathering, Analysis and Retrieval

system or any successor system (“EDGAR”), upon the request of the Underwriter, to furnish promptly to the Underwriter

and to counsel for the Underwriter a signed copy of the Registration Statement as originally filed with the Commission, and of each amendment

thereto filed with the Commission, including all consents and exhibits filed therewith.

(h)            Delivery

of Copies. Upon request of the Underwriter, to the extent not available on EDGAR, to deliver promptly to the Underwriter in New York

City such number of the following documents as the Underwriter shall reasonably request: (i) conformed copies of the Registration

Statement as originally filed with the Commission (in each case excluding exhibits), (ii) each Preliminary Prospectus, (iii) any

Issuer Free Writing Prospectus, (iv) the Prospectus (the delivery of the documents referred to in clauses (i), (ii), (iii) and

(iv) of this paragraph (h) to be made not later than 10:00 A.M., New York time, on the business day following the execution

and delivery of this Agreement), (v) conformed copies of any amendment to the Registration Statement (excluding exhibits), (vi) any

amendment or supplement to the General Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (v) and

(vi) of this paragraph (h) to be made not later than 10:00 A.M., New York City time, on the business day following the date

of such amendment or supplement) and (vii) any document incorporated by reference in the General Disclosure Package or the Prospectus

(excluding exhibits thereto) (the delivery of the documents referred to in clause (vi) of this paragraph (h) to be made not

later than 10:00 A.M., New York City time, on the business day following the date of such document).

(i)             Blue

Sky Compliance. To take promptly from time to time such actions as the Underwriter may reasonably request to qualify the Securities

for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Underwriter may reasonably

designate and to continue such qualifications in effect, and to comply with such laws, for so long as required to permit the offer and

sale of Securities in such jurisdictions; provided that the Company shall not be obligated to (i) qualify as a foreign corporation

in any jurisdiction in which it is not so qualified, (ii) file a general consent to service of process in any jurisdiction or (iii) subject

itself to taxation in any such jurisdiction if it is not otherwise so subject.

(j)             Reports.

Upon request, during the period of five (5) years from the date hereof, to deliver to the Underwriter, (i) as soon as they are

available, copies of all reports or other communications (financial or other) furnished to stockholders, and (ii) as soon as they

are available, copies of any reports and financial statements furnished or filed with the Commission or any national securities exchange

on which the Common Stock is listed. However, so long as the Company is subject to the reporting requirements of either Section 13

or Section 15(d) of the Exchange Act and is timely filing reports with the Commission on EDGAR, it is not required to furnish

such reports or statements to the Underwriter.

(k)            Lock-Up.

During the period commencing on and including the date hereof and ending on and including the ninetieth (90th) day following the date

of this Agreement (the “Lock-Up Period”), the Company will not, without the prior written consent of the Underwriter

(which consent may be withheld at the sole discretion of the Underwriter), directly or indirectly offer, sell (including, without limitation,

any short sale), assign, transfer, pledge, contract to sell, establish an open “put equivalent position” within the meaning

of Rule 16a-1(h) under the Exchange Act, or otherwise dispose of, or announce the offering of, or file any registration statement

under the Securities Act in respect of, any Common Stock, options, rights or warrants to acquire Common Stock or securities exchangeable

or exercisable for or convertible into Common Stock (other than is contemplated by this Agreement with respect to the Securities) or publicly

announce any intention to do any of the foregoing; provided, however, that the Company may (i) issue Common Stock, options to purchase

Common Stock, restricted stock units, and other equity awards, shares of Common Stock underlying options, restricted stock units and other

equity awards granted and other securities, each pursuant to any director or employee stock incentive plan, other equity incentive plan,

stock ownership plan or dividend reinvestment plan of the Company in effect on the date hereof and described in the General Disclosure

Package; (ii) issue Common Stock pursuant to the conversion of securities or the exercise of warrants, which securities or warrants

are outstanding on the date hereof and described in the General Disclosure Package, as well as the Warrant Shares upon exercise of Accompanying

Warrants; (iii) adopt a new equity incentive plan, amend any existing equity incentive plan (including without limitation, to increase

the number of shares reserved for issuance thereunder) and file a registration statement on Form S-8 under the Securities Act to

register the offer and sale of securities to be issued pursuant to such new equity incentive plan or amended equity incentive plan, and

issue securities pursuant to such new equity incentive plan or amended equity incentive plan (including, without limitation, the issuance

of shares of Common Stock upon the exercise of options or other securities issued pursuant to such new equity incentive plan or amended

equity incentive plan), provided that (1) such new equity incentive plan or amended equity incentive plan satisfies the transaction

requirements of General Instruction A.1 of Form S-8 under the Securities Act and (2) this clause (iii) shall not be available

unless each recipient of shares of Common Stock, or securities exchangeable or exercisable for or convertible into Common Stock, (A) pursuant

to such new equity incentive plan or (B) representing the additional shares reserved for issuance under such existing equity incentive

plan pursuant to such amendment to such existing equity incentive plan, shall be contractually prohibited from selling, offering, disposing

of or otherwise transferring any such shares or securities during the remainder of the Lock-Up Period; (iv) enter into an agreement

providing for the issuance of Common Stock or securities convertible into or exercisable for shares of Common Stock in connection with

any acquisition, joint venture, collaboration, licensing, commercial relationship or other strategic transaction or any debt financing

transaction, and the issuance of any such securities pursuant to any such agreement, provided that the aggregate number of shares of Common

Stock, or any securities convertible into or exercisable or exchangeable for Common Stock, that the Company may issue or agree to issue

pursuant to this clause (iv) shall not exceed 5% of the total outstanding shares of Common Stock immediately following the issuance

of the Securities pursuant hereto; and (vi) issue shares of Common Stock pursuant to the Equity Distribution Agreement, dated December 11,

2024, between the Company and Oppenheimer & Co. Inc., as sales agent, or any replacement “at the market” offering

program (the “ATM”), provided that the Lock-Up Period applicable to this clause (vi) shall commence on and include

the date hereof and end on and include the sixtieth (60th) day following the date of this Agreement, and provided further, that for the

remainder of the Lock-Up Period, the Company shall only sell shares of Common Stock or issue a sales notice pursuant to the ATM if the

price per share of Common Stock is above $2.50. The Company will cause all executive officers and directors of the Company listed on Schedule

E attached hereto to furnish to the Underwriter, prior to the Closing Date, the “lock-up” agreement substantially in the

form of Exhibit I hereto.

(l)             Delivery

of SEC Correspondence. To supply the Underwriter with copies of all correspondence to and from, and all documents issued to and by,

the Commission in connection with the registration of the Securities under the Securities Act or any of the Registration Statement, any

Preliminary Prospectus or the Prospectus, or any amendment or supplement thereto or document incorporated by reference therein.

(m)           Press

Releases. Prior to the Closing Date, not to issue any press release or other communication directly or indirectly or hold any press

conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects (except

for routine oral marketing communications in the ordinary course of business and consistent with the past practices of the Company and

of which the Underwriter is notified), without the prior consent of the Underwriter, unless in the judgment of the Company and its counsel,

and after notification to the Underwriter, such press release or communication is required by law.

(n)            Compliance

with Regulation M. Until the Underwriter shall have notified the Company of the completion of the resale of the Securities, that the

Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation M under the Exchange

Act) not to, either alone or with one or more other persons, bid for or purchase, for any account in which it or any of its affiliated

purchasers has a beneficial interest, any Securities, or attempt to induce any person to purchase any Securities; and not to, and to use

its reasonable best efforts to cause its affiliated purchasers not to, make bids or purchase for the purpose of creating actual, or apparent,

active trading in or of raising the price of the Securities.

(o)            Registrar,

Transfer Agent and Warrant Agent. To maintain, at its expense, a registrar and transfer agent for the Shares and a warrant agent for

the Accompanying Warrants.

(p)            Use

of Proceeds. To apply the net proceeds from the sale of the Securities as set forth in the Registration Statement, the General Disclosure

Package and the Prospectus under the heading “Use of Proceeds,” and except as disclosed in the General Disclosure Package,

the Company does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to

any affiliate of the Underwriter.

(q)            Exchange

Listing. To use its reasonable best efforts to list for quotation the Shares and the Warrant Shares on the Exchange.

(r)             Performance

of Covenants and Satisfaction of Conditions. To use its reasonable best efforts to do and perform all things required to be done or

performed under this Agreement by the Company prior to the Closing Date and to satisfy all conditions precedent to the delivery of the

Securities.

(s)            License

to use Marks. Upon request of the Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of

the Company’s trademarks, service marks and corporate logo for use on the website, if any, operated by such Underwriter for the

purpose of facilitating the on-line offering of the Securities (the “License”); provided, however, that the License

shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred.

(t)            Share

Reserve. The Company will reserve and keep available at all times a sufficient number of shares of Common Stock for the purpose of

enabling the Company to issue the Warrant Shares.

(u)            Registration

Statement for the Accompanying Warrants. The Company will, at all times while any of the Accompanying Warrants are outstanding and

exercisable, use its commercially reasonable efforts to maintain a registration statement covering the issue and sale of the Warrant Shares

upon exercise of the Accompanying Warrants such that the Warrant Shares, when issued, will not be subject to resale restrictions under

the Securities Act except to the extent that the Warrant Shares are owned by affiliates.

5.             PAYMENT

OF EXPENSES. The Company agrees to pay, or reimburse if paid by the Underwriter, whether or not the transactions contemplated hereby are

consummated or this Agreement is terminated: (a) the costs incident to the authorization, issuance, sale, preparation and delivery

of the Securities and any taxes payable in that connection; (b) the costs incident to the registration of the Securities under the

Securities Act; (c) the costs incident to the preparation, printing and distribution of the Registration Statement, the Base Prospectus,

any Preliminary Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any amendments, supplements

and exhibits thereto or any document incorporated by reference therein and the costs of printing, reproducing and distributing this Agreement,

the Accompanying Warrants and any closing documents by mail, telex or other means of communications; (d) the fees and expenses (including,

subject to clause (j), related fees and expenses of counsel for the Underwriter) incurred in connection with securing any required review

by FINRA of the terms of the sale of the Securities and any filings made with FINRA; (e) any applicable listing or other fees; (f) the

fees and expenses (including, subject to clause (j), related fees and expenses of counsel to the Underwriter) of qualifying the Securities

under the securities laws of the several jurisdictions as provided in Section 4(i) and of preparing, printing and distributing

wrappers, Blue Sky Memoranda and Legal Investment Surveys; (g) the cost of preparing and printing stock certificates; (h) all

fees and expenses of the registrar, transfer agent and warrant agent of the Shares and Accompanying Warrants, as applicable; (i) the

expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing

of the offering of the Securities, including, without limitation, expenses associated with the preparation or dissemination of any electronic

road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection

with the road show presentations with the prior approval of the Company, travel and lodging expenses of the officers of the Company and

such consultants; (j) the fees and expenses of counsel to the Underwriter in an amount not to exceed an aggregate of $100,000 (inclusive

of amounts reimbursed pursuant to clauses (d) and (f) of this Section 5); and (k) all other costs and expenses incurred

by the Company incident to the offering of the Securities or the performance of the obligations of the Company under this Agreement (including,

without limitation, the fees and expenses of the Company’s counsel and the Company’s independent accountants); provided that,

except to the extent otherwise provided in this Section 5 and in Section 9, the Underwriter shall pay its own costs and expenses,

including the fees and expenses of its counsel not contemplated herein, any transfer taxes on the resale of any Securities by it and the

expenses of advertising any offering of the Securities made by the Underwriter.

6.             CONDITIONS

OF UNDERWRITER’S OBLIGATIONS. The obligations of the Underwriter hereunder are subject to the accuracy, when made and as of the

Applicable Time and on the Closing Date, of the representations and warranties of the Company contained herein, to the accuracy of the

statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations

hereunder, and to each of the following additional terms and conditions:

(a)            Registration

Compliance; No Stop Orders. The Registration Statement has become effective under the Securities Act, and no stop order suspending

the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of any Base Prospectus, any Preliminary

Prospectus, the Prospectus or any Permitted Free Writing Prospectus or any part thereof shall have been issued and no proceedings for

that purpose or pursuant to Section 8A under the Securities Act shall have been initiated or threatened by the Commission, and all

requests for additional information on the part of the Commission (to be included or incorporated by reference in the Registration Statement

or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Underwriter; the Rule 462(b) Registration

Statement, if any, each Issuer Free Writing Prospectus and the Prospectus shall have been filed with the Commission within the applicable

time period prescribed for such filing by, and in compliance with, the Rules and Regulations and in accordance with Section 4(a),

and the Rule 462(b) Registration Statement, if any, shall have become effective immediately upon its filing with the Commission;

and FINRA shall have raised no unresolved objection to the fairness and reasonableness of the terms of this Agreement or the transactions

contemplated hereby.

(b)            No

Material Misstatements. The Underwriter shall not have discovered and disclosed to the Company on or prior to the Closing Date that

the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the opinion of counsel

for the Underwriter, is material or omits to state any fact which, in the opinion of such counsel, is material and is required to be stated

therein or is necessary to make the statements therein not misleading, or that the General Disclosure Package, any Issuer Free Writing

Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which, in the opinion of such

counsel, is material or omits to state any fact which, in the opinion of such counsel, is material and is necessary in order to make the

statements, in the light of the circumstances in which they were made, not misleading.

Proceedings. All corporate proceedings incident to the authorization, form and validity of each of this Agreement, the Securities,

the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus and the Prospectus and the transactions

contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Underwriter, and the Company shall have

furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon such matters.

(d)            Opinion

and 10b-5 Statement of Counsel for the Company. Loeb & Loeb LLP shall have furnished to the Underwriter such counsel’s

written opinion and negative assurance statement, as counsel to the Company, addressed to the Underwriter and dated the Closing Date,

in form and substance reasonably satisfactory to the Underwriter.

(e)            Opinion

of Intellectual Property Counsel for the Company. Each of (i) Duane Morris LLP and (ii) Davidson Kappel LLC, intellectual

property counsels to the Company, shall have furnished to the Underwriter such counsel’s written opinion, as intellectual property

counsel to the Company, addressed to the Underwriter and dated the Closing Date, in form and substance reasonably satisfactory to the

Underwriter.

(f)             Opinion

and 10b-5 Statement of Counsel for the Underwriter. The Underwriter shall have received from Mintz, Levin, Cohn, Ferris, Glovsky and

Popeo, P.C., counsel for the Underwriter, such opinion or opinions and negative assurance statement, dated the Closing Date, with respect

to such matters as the Underwriter may reasonably require, and the Company shall have furnished to such counsel such documents as they

request for enabling them to pass upon such matters.

(g)            Comfort

Letters. At the time of the execution of this Agreement, the Underwriter shall have received from Ernst & Young LLP, which

served and serves as the independent registered public accounting firm for the Company, a letter addressed to the Underwriter, executed

and dated such date, in form and substance reasonably satisfactory to the Underwriter (i) confirming that they are an independent

registered accounting firm with respect to the Company within the meaning of the Securities Act and the Rules and Regulations and

PCAOB and (ii) stating the conclusions and findings of such firm, of the type ordinarily included in accountants’ “comfort

letters” to underwriters for offerings similar to that contemplated by this Agreement, with respect to the financial statements

and certain financial information contained or incorporated by reference in the Registration Statement, the General Disclosure Package

and the Prospectus.

(h)            Bring

Down Comfort. On the effective date of any post-effective amendment to the Registration Statement and on the Closing Date, the Underwriter

shall have received a letter (a “bring-down letter”) from Ernst & Young LLP addressed to the Underwriter and

dated the Closing Date confirming, as of the date of such bring-down letter (or, with respect to matters involving changes or developments

since the respective dates as of which specified financial information is given in the General Disclosure Package and the Prospectus,

as the case may be, as of a date not more than two (2) business days prior to the date of such bring-down letter), the conclusions

and findings of such firm, of the type ordinarily included in accountants’ “comfort letters” to underwriters for offerings

similar to that contemplated by this Agreement, with respect to the financial information and other matters covered by such letter delivered

to the Underwriter concurrently with the execution of this Agreement pursuant to paragraph (g) of this Section 6.

(i)             Officer’s

Certificate. The Company shall have furnished to the Underwriter a certificate, dated the Closing Date, of its President and Chief

Executive Officer stating in such Officer’s capacity as an officer of the Company on behalf of the Company that (i) no stop

order suspending the effectiveness of the Registration Statement (including, for avoidance of doubt, any Rule 462(b) Registration

Statement), or any post-effective amendment thereto, shall be in effect and no proceedings for such purpose shall have been instituted

or, to their knowledge, threatened by the Commission, (ii) for the period from and including the date of this Agreement through and

including the Closing Date, there has not occurred any Material Adverse Change, (iii) to her knowledge, after reasonable investigation,

as of the Closing Date, the representations and warranties of the Company in this Agreement are true and correct and the Company has complied

with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, and

(iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference

in the General Disclosure Package, any Material Adverse Change in the financial position or results of operations of the Company, or any

change or development that, singularly or in the aggregate, would reasonably be expected to have a Material Adverse Change, except as

set forth in the General Disclosure Package and the Prospectus.

(j)             No

Material Adverse Change. Since the date of the latest audited financial statements included in the General Disclosure Package or incorporated

by reference in the General Disclosure Package as of the date hereof, (i) the Company shall not have sustained any loss or interference

with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court

or governmental action, order or decree, otherwise than as set forth in the General Disclosure Package, and (ii) there shall not

have been any change in the capital stock (other than upon the exercise of any stock option or vesting of any equity award, in each case,

outstanding as of the date hereof, the grant of any stock option or other stock award under existing equity plans or the exercise of any

warrants outstanding as of the date hereof, in each case, as set forth in the General Disclosure Package) or increase in the long-term

debt of the Company, or any change, or any development involving a prospective change, in or affecting the business, general affairs,

management, financial position, stockholders’ equity or results of operations of the Company, otherwise than as set forth in the

General Disclosure Package, the effect of which, in any such case described in clause (i) or (ii) of this paragraph (j), is,

in the judgment of the Underwriter, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery

of the Securities on the terms and in the manner contemplated in the General Disclosure Package.

(k)            No

Legal Impediment to Issuance. No action shall have been taken and no law, statute, rule, regulation or order shall have been enacted,

adopted or issued by any governmental or regulatory agency or body which would prevent the issuance or sale of the Securities; and no

injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued

which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially materially and adversely

affect the business or operations of the Company.

(l)             [Reserved].

(m)           Market

Conditions. Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following: (i) trading

in any of the Company’s securities shall have been suspended or materially limited by the Commission or the Exchange, or trading

in securities generally on the New York Stock Exchange, Nasdaq Global Select Market, Nasdaq Global Market, Nasdaq Capital Market or the

NYSE American LLC or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter

market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established

on any such exchange or such market by the Commission, by such exchange or market or by any other regulatory body or governmental authority

having jurisdiction, (ii) a banking moratorium shall have been declared by Federal or state authorities or a material disruption

has occurred in commercial banking or securities settlement or clearance services in the United States, (iii) the United States shall

have become engaged in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of or escalation in hostilities

involving the United States, or there shall have been a declaration of a national emergency or war by the United States or (iv) there

shall have occurred such a material adverse change in general economic, political or financial conditions (or the effect of international

conditions on the financial markets in the United States shall be such) as to make it, in the judgment of the Underwriter, impracticable

or inadvisable to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated in the General Disclosure

Package and the Prospectus.

(n)            Exchange

Listing. The Company shall have submitted a Supplemental Listing Application with the Exchange and shall have received approval thereto

from the Exchange.

(o)            Good

Standing. The Underwriter shall have received on and as of the Closing Date satisfactory evidence of the good standing of the Company

in its jurisdiction of organization and its good standing as a foreign entity in such other jurisdictions as the Underwriter may reasonably

request, in each case in writing or any standard form of telecommunication from the appropriate Governmental Authorities of such jurisdictions.

(p)            Lock-Up

Agreements. The Underwriter shall have received the written agreements, substantially in the form of Exhibit I hereto,

of all executive officers and directors of the Company listed on Schedule E attached hereto.

(q)            Secretary’s

Certificate. The Company shall have furnished to the Underwriter a Secretary’s Certificate of the Company, in form and substance

reasonably satisfactory to counsel for the Underwriter and customary for the type of offering contemplated by this Agreement.

(r)            Acting

Chief Financial Officer’s Certificate. The Company shall have furnished to the Underwriter an Acting Chief Financial Officer’s

Certificate of the Company, as needed, in form and substance reasonably satisfactory to counsel for the Underwriter and customary for

the type of offering contemplated by this Agreement, with respect to certain financial information of the Company included in the General

Disclosure Package and the Prospectus.

(s)            Accompanying

Warrants. The Underwriter shall have received copies, duly executed by the Company, of the Accompanying Warrants. There shall exist

no event or condition which would constitute a default or an event of default under the Accompanying Warrants.

(t)            Additional

Documents. On or prior to the Closing Date, the Company shall have furnished to the Underwriter such further customary certificates

and documents as the Underwriter may reasonably request.

All opinions, letters, evidence

and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if

they are in form and substance reasonably satisfactory to counsel for the Underwriter.

7.             INDEMNIFICATION

AND CONTRIBUTION.

(a)            Indemnification

of Underwriter by the Company. The Company shall indemnify and hold harmless the Underwriter, its affiliates, directors, officers,

managers, members, employees, representatives and agents and each person, if any, who controls the Underwriter within the meaning of Section 15

of the Securities Act or Section 20 of the Exchange Act (collectively the “Underwriter Indemnified Parties,” and

each an “Underwriter Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever (or any action,

investigation or proceeding in respect thereof), joint or several, to which such Underwriter Indemnified Party may become subject, under

the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out

of or is based upon (A) any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus,

any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) of

the Rules and Regulations, the Registration Statement, the Prospectus, or in any amendment or supplement thereto or document incorporated

by reference therein or in any materials or information provided to investors by, or with the approval of, the Company in connection with

the marketing of the offering of the Securities, including any roadshow or investor presentations made to investors by the Company (whether

in person or electronically) (“Marketing Materials”) or (B) the omission or alleged omission to state in any Preliminary

Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) of

the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated

by reference therein or in any Marketing Materials, a material fact required to be stated therein or necessary to make the statements

therein not misleading, and shall reimburse each Underwriter Indemnified Party promptly upon demand for any legal fees or other expenses

reasonably incurred by that Underwriter Indemnified Party in connection with investigating, or preparing to defend, or defending against,

or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense,

liability, action, investigation or proceeding, as such fees and expenses are incurred; provided, however, that the Company shall not

be liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue

statement or alleged untrue statement in, or omission or alleged omission from any Preliminary Prospectus, the Registration Statement

or the Prospectus, or any such amendment or supplement thereto, any Issuer Free Writing Prospectus or any Marketing Materials made in

reliance upon and in conformity with written information furnished to the Company through the Underwriter specifically for use therein,

which information the parties hereto agree is limited to the Underwriter’s Information.

The indemnity agreement in

this Section 7(a) is not exclusive and is in addition to each other liability which the Company might have under this Agreement

or otherwise, and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to

any Underwriter Indemnified Party.

(b)            Indemnification

of Company by the Underwriter. The Underwriter shall indemnify and hold harmless the Company and its directors, its officers who signed

the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act

or Section 20 of the Exchange Act (collectively the “Company Indemnified Parties” and each a “Company

Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding

in respect thereof), joint or several, to which such Company Indemnified Party may become subject, under the Securities Act or otherwise,

insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon (i) any

untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus,

any “issuer information” filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations,

the Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein,

or (ii) the omission or alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer

information” filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration

Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, a material fact

required to be stated therein or necessary to make the statements therein not misleading, but in each case only to the extent that the

untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written

information furnished to the Company through the Underwriter specifically for use therein, which information the parties hereto agree

is limited to the Underwriter’s Information, and shall reimburse the Company Indemnified Parties for any legal or other expenses

reasonably incurred by such party in connection with investigating or preparing to defend or defending against or appearing as third party

witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees and expenses are

incurred. This indemnity agreement is not exclusive and will be in addition to any liability which the Underwriter might otherwise have

and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to the Company Indemnified

Parties.

after receipt by an indemnified party under this Section 7 of notice of the commencement of any action, the indemnified party shall,

if a claim in respect thereof is to be made against an indemnifying party under this Section 7, notify such indemnifying party in

writing of the commencement of that action; provided, however, that the failure to notify the indemnifying party shall not relieve it

from any liability which it may have under this Section 7 except to the extent it has been materially prejudiced by such failure;

and, provided, further; that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to

an indemnified party otherwise than under this Section 7. If any such action shall be brought against an indemnified party, and it

shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it

wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action with counsel reasonably satisfactory

to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel to the indemnifying

party). After notice from the indemnifying party to the indemnified party of its election to assume the defense of such action, except

as provided herein, the indemnifying party shall not be liable to the indemnified party under Section 7 for any legal or other expenses

subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable costs of investigation;

provided, however; that any indemnified party shall have the right to employ separate counsel in any such action and to participate in

the defense of such action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense

of such indemnified party unless (i) the employment thereof has been specifically authorized in writing by the Company in the case

of a claim for indemnification under Section 7(a) or the Underwriter in the case of a claim for indemnification under Section 7(b),

(ii) such indemnified party shall have been advised by its counsel that there may be one or more legal defenses available to it which

are different from or additional to those available to the indemnifying party, or (iii) the indemnifying party has failed to assume

the defense of such action and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after

notice of the commencement of the action or the indemnifying party does not diligently defend the action after assumption of the defense,

in which case, if such indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense

of the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to diligently

defend the action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party and the indemnifying

party shall be responsible for legal or other expenses subsequently incurred by such indemnified party in connection with the defense

of such action; provided, however, that the indemnifying party shall not, in connection with any one such action or separate but substantially

similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable

fees and expenses of more than one separate firm of attorneys at any time for all such indemnified parties (in addition to any local counsel),

which firm shall be designated in writing by the Underwriter if the indemnified parties under this Section 7 consist of any Underwriter

Indemnified Party or by the Company if the indemnified parties under this Section 7 consist of any Company Indemnified Parties. Subject

to this Section 7(c), the amount payable by an indemnifying party under Section 7 shall include, but not be limited to, (x) reasonable

legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending

against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any action, investigation, proceeding

or claim, and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written

consent of the indemnified parties, settle or compromise or consent to the entry of judgment with respect to any pending or threatened

action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this Section 7 (whether

or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes

an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party from all liability

arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure

to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party shall be liable

for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent

shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been unreasonably withheld

or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless

any indemnified party from and against any loss or liability by reason of such settlement or judgment. In addition, if at any time an

indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such

indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Sections 7(a) or 7(b) effected

without its written consent if (i) such settlement is entered into more than forty-five (45) days after receipt by such indemnifying

party of the request for reimbursement, (ii) such indemnifying party shall have received notice of the terms of such settlement at

least thirty (30) days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such

indemnified party in accordance with such request prior to the date of such settlement.

(d)            If

the indemnification provided for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under Section 7(a) or

7(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable or otherwise

incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding

in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the

Company on the one hand and the Underwriter on the other from the offering of the Securities, or (ii) if the allocation provided

by clause (i) of this Section 7(d) is not permitted by applicable law, in such proportion as is appropriate to reflect

not only the relative benefits referred to in clause (i) of this Section 7(d) but also the relative fault of the Company

on the one hand and the Underwriter on the other with respect to the statements, omissions, acts or failures to act which resulted in

such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant

equitable considerations. The relative benefits received by the Company on the one hand and the Underwriter on the other with respect

to such offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Securities purchased

under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received

by the Underwriter with respect to the Securities purchased under this Agreement, in each case as set forth in the table on the cover

page of the Prospectus. The relative fault of the Company on the one hand and the Underwriter on the other shall be determined by

reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission

to state a material fact relates to information supplied by the Company on the one hand or the Underwriter on the other, the intent of

the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission,

act or failure to act; provided that the parties hereto agree that the written information furnished to the Company through the Underwriter

for use in the Preliminary Prospectus, the Registration Statement or the Prospectus, or in any amendment or supplement thereto, consists

solely of the Underwriter’s Information.

(e)            The

Company and the Underwriter agree that it would not be just and equitable if contributions pursuant to Section 7(d) above were

to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations

referred to Section 7(d) above. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense,

liability, action, investigation or proceeding referred to in Section 7(d) above shall be deemed to include, subject to the

limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating,

preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with,

any such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section 7,

the Underwriter shall not be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions

received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages which the Underwriter has

otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or alleged

act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(t) of

the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

8.             TERMINATION.

The obligations of the Underwriter hereunder may be terminated by the Underwriter, in its absolute discretion by notice given to the Company

prior to delivery of and payment for the Securities if, prior to that time, any of the events described in Sections 6(j) or 6(m) have

occurred or if the Underwriter shall decline to purchase the Securities for any reason permitted under this Agreement.

9.             REIMBURSEMENT

OF UNDERWRITER’S EXPENSES. Notwithstanding anything to the contrary in this Agreement, if (a) this Agreement shall have been

terminated pursuant to Section 8, (b) the Company shall fail to tender the Securities for delivery to the Underwriter for any

reason not permitted under this Agreement, (c) the Underwriter shall decline to purchase the Securities for any reason permitted

under this Agreement or (d) the sale of the Securities is not consummated because any condition to the obligations of the Underwriter

set forth herein is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement

herein or to satisfy any condition or to comply with the provisions hereof, then in addition to the payment of amounts in accordance with

Section 5, the Company shall, pro rata based on the number of Securities it agreed to sell hereunder, reimburse the Underwriter for

the reasonable and documented fees and expenses of Underwriter’s counsel and for such other reasonable and documented out-of-pocket

expenses as shall have been reasonably incurred by them in connection with this Agreement and the proposed purchase of the Securities,

including, without limitation, reasonable travel and lodging expenses of the Underwriter, and upon demand the Company shall pay the full

amount thereof to the Underwriter not to exceed $25,000 in the aggregate.

10.           [RESERVED].

11.           ABSENCE

OF FIDUCIARY RELATIONSHIP. The Company acknowledges and agrees that:

(a)            the

Underwriter’s responsibility to the Company is solely contractual in nature, the Underwriter has been retained solely to act as

underwriter in connection with the sale of the Securities and no fiduciary, advisory or agency relationship between the Company and the

Underwriter have been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Underwriter

has advised or is advising the Company on other matters;

(b)            the

price of the Shares and Accompanying Warrants set forth in this Agreement was established by the Company following discussions and arms-length

negotiations with the Underwriter, and the Company is capable of evaluating and understanding, and understands and accepts, the terms,

risks and conditions of the transactions contemplated by this Agreement;

has been advised that the Underwriter and its affiliates are engaged in a broad range of transactions which may involve interests that

differ from those of the Company and that the Underwriter has no obligation to disclose such interests and transactions to the Company

by virtue of any fiduciary, advisory or agency relationship; and

(d)            it

waives, to the fullest extent permitted by law, any claims it may have against the Underwriter for breach of fiduciary duty or alleged

breach of fiduciary duty and agrees that the Underwriter shall have no liability (whether direct or indirect) to the Company in respect

of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders,

employees or creditors of the Company.

12.           SUCCESSORS;

PERSONS ENTITLED TO BENEFIT OF AGREEMENT. This Agreement shall inure to the benefit of and be binding upon the Underwriter, the Company

and their respective successors and assigns. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give

any person, other than the persons mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or in respect

of this Agreement, or any provisions herein contained, this Agreement and all conditions and provisions hereof being intended to be and

being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations, warranties,

covenants, agreements and indemnities of the Company contained in this Agreement shall also be for the benefit of the Underwriter Indemnified

Parties, and the indemnities of the Underwriter shall be for the benefit of the Company Indemnified Parties. It is understood that the

Underwriter’s responsibility to the Company is solely contractual in nature and the Underwriter does not owe the Company, or any

other party, any fiduciary duty as a result of this Agreement. No purchaser of any of the Securities from the Underwriter shall be deemed

to be a successor or assign by reason merely of such purchase.

13.           SURVIVAL

OF INDEMNITIES, REPRESENTATIONS, WARRANTIES, ETC. The respective indemnities, covenants, agreements, representations, warranties

and other statements of the Company and the Underwriter, as set forth in this Agreement or made by them respectively, pursuant to this

Agreement, shall remain in full force and effect, regardless of any investigation made by or on behalf of the Underwriter, the Company

or any person controlling any of them and shall survive delivery of and payment for the Securities. Notwithstanding any termination of

this Agreement, including without limitation any termination pursuant to Section 8, the indemnities, covenants, agreements, representations,

warranties and other statements forth in Sections 2, 5, 7 and 9 and Sections 11 through 21, inclusive, of this Agreement shall not terminate

and shall remain in full force and effect at all times.

14.           RECOGNITION

OF THE U.S. SPECIAL RESOLUTION REGIMES.

(a)            In

the event that the Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer

from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent

as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were

governed by the laws of the United States or a state of the United States.

(b)            In

the event that the Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under

a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to

be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement

were governed by the laws of the United States or a state of the United States.

15.           NOTICES.

All statements, requests, notices and agreements hereunder shall be in writing, and:

(a)            if

to the Underwriter, shall be delivered or sent by mail to Canaccord Genuity LLC, Penn 1, One Pennsylvania Plaza, Suite 2900, New

York, NY 10119, Attention: General Counsel, with a copy to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 919 Third Avenue, New

York, NY 10022, Attention: Ivan Blumenthal; and

(b)            if

to the Company, shall be delivered or sent by mail, telex, facsimile transmission or email to Annovis Bio, Inc., 101 Lindenwood Drive,

Suite 225, Malvern, PA 19355, Attention: Chief Executive Officer, with a copy to Loeb & Loeb LLP, 345 Park Avenue, New York,

NY 10154, Attention: Joan Guilfoyle.

16.           DEFINITION

OF CERTAIN TERMS. For purposes of this Agreement, (a) “affiliate” has the meaning set forth in Rule 405 under

the Securities Act, (b) “business day” means any day on which the Exchange is open for trading and (c) “subsidiary”

has the meaning set forth in Rule 405 of the Rules and Regulations; (d) “BHC Act Affiliate” has the

meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k), (e) “Covered

Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance

with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with,

12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12

C.F.R. § 382.2(b), (f) “Default Right” has the meaning assigned to that term in, and shall be interpreted

in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable, (g) “U.S. Special Resolution Regime”

means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title H of the Dodd-Frank

Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

17.           GOVERNING

LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including without limitation

Section 5-1401 of the New York General Obligations. The Company irrevocably (a) submits to the exclusive jurisdiction of the

Federal and state courts in the Borough of Manhattan in The City of New York for the purpose of any suit, action or other proceeding arising

out of this Agreement or the transactions contemplated by this Agreement, the Registration Statement and any Preliminary Prospectus or

the Prospectus, (b) agrees that all claims in respect of any such suit, action or proceeding may be heard and determined by any such

court, (c) waives to the fullest extent permitted by applicable law, any immunity from the jurisdiction of any such court or from

any legal process, (d) agrees not to commence any such suit, action or proceeding other than in such courts, and (e) waives,

to the fullest extent permitted by applicable law, any claim that any such suit, action or proceeding is brought in an inconvenient forum.

THE COMPANY AND THE UNDERWRITER HEREBY WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER BASED UPON CONTRACT, TORT OR

OTHERWISE) IN ANY WAY ARISING OUT OF OR RELATING TO THIS AGREEMENT. THE COMPANY AND THE UNDERWRITER HEREBY AGREE THAT A FINAL JUDGMENT

IN ANY SUCH LEGAL PROCEEDING BROUGHT IN ANY SUCH COURT SHALL BE CONCLUSIVE AND BINDING UPON THE COMPANY OR THE UNDERWRITER, AS APPLICABLE,

AND MAY BE ENFORCED IN ANY OTHER COURTS IN THE JURISDICTION OF WHICH THE COMPANY OR THE UNDERWRITER, AS APPLICABLE, IS OR MAY BE

SUBJECT, BY SUIT UPON SUCH JUDGMENT.

18.           UNDERWRITER’S

INFORMATION. The parties hereto acknowledge and agree that, for all purposes of this Agreement, the Underwriter’s Information consists

solely of the statements concerning the Underwriter contained in the following paragraphs under the heading “Underwriting”

in the Prospectus: (i) the third paragraph under “- Discounts”; (ii) the paragraph under “-Discretionary Accounts”;

(iii) the paragraphs under “-Stabilization”; (iv) the paragraph under “-Passive Market Making”; and

(v) the paragraph under “-Electronic Offer, Sale and Distribution of Securities.”

19.           PARTIAL

UNENFORCEABILITY. The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect

the validity or enforceability of any other section, paragraph, clause or provision hereof. If any section, paragraph, clause or provision

of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and

only such minor changes) as are necessary to make it valid and enforceable.

20.           GENERAL.

This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous

oral agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine

and neuter genders and the singular and the plural include one another. The section headings in this Agreement are for the convenience

of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may be amended or modified,

and the observance of any term of this Agreement may be waived, only by a writing signed by the Company and the Underwriter.

21.           COUNTERPARTS.

This Agreement may be signed in any number of counterparts, each of which shall be an original, including by facsimile or other electronic

transmission, with the same effect as if the signatures thereto and hereto were upon the same instrument.

[Signature pages follow]

If the foregoing is in accordance

with your understanding please indicate your acceptance of this Agreement by signing in the space provided for that purpose below.

Very truly yours,

ANNOVIS BIO, INC.

By:

/s/ Maria Maccecchini

Name: Maria Maccecchini

Title: President and Chief Executive Officer

Accepted as of the date first above written:

CANACCORD GENUITY LLC

By:

/s/ Jennifer Pardi

Name: Jennifer Pardi

Title: Managing Director

SCHEDULE A

Name

Number of

Shares to be

Purchased

Number of

Accompanying

Warrants to be

Purchased

Canaccord Genuity LLC

5,263,156

Total

5,263,156

SCHEDULE B

General Use Free Writing Prospectuses

None.

SCHEDULE C

Pricing Information

Securities to be Sold:

5,263,156 shares of Common Stock

Accompanying Warrants to purchase

5,263,156 shares of Common Stock

Offering Price:

$1.90 per share of Common Stock and Accompanying Warrant

Accompanying Warrant Exercise Price:

$2.50 per Warrant Share

Underwriting Discounts and Commissions:

6.5%

SCHEDULE D

Testing-the-Waters Communications

None.

SCHEDULE E

Lock-Up Parties

Maria L. Maccecchini, Ph.D.

Michael B. Hoffman

Reid S. McCarthy

Claudine E. Bruck, Ph.D.

Mark White

EXHIBIT I

Form of Lock-Up Agreement

Form of Lockup Agreement

April __ , 2026

Canaccord Genuity LLC

Penn 1, One Pennsylvania Plaza, Suite 2900

New York, NY 10119

Re: Proposed Registered Direct Offering by

Annovis Bio, Inc.

Ladies and Gentlemen:

The undersigned, a securityholder

and/or officer and/or a director of Annovis Bio, Inc., a Delaware corporation (the “Company”), understands that

Canaccord Genuity LLC (“Canaccord”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”)

with the Company relating to the proposed underwritten registered direct offering (the “Offering”) of shares (the “Shares”)

of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and warrants exercisable for

shares of Common Stock (the “Warrants” and together with the Shares, the “Securities”). The undersigned

acknowledges that Canaccord is relying on the representations and agreements of the undersigned contained in this lock-up agreement in

conducting the Offering and, at a subsequent date, in entering into the Underwriting Agreement and other underwriting arrangements with

the Company with respect to the Offering.

In recognition of the benefit

that the Offering will confer upon the undersigned as a securityholder and/or officer and/or a director of the Company, and for other

good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees that, during the

period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the “Lock-Up

Period”), the undersigned will not (and will cause any immediate family member not to), without the prior written consent of

Canaccord, which may withhold its consent in its sole discretion, directly or indirectly, (i) sell, offer to sell, contract to sell

or lend, effect any short sale or establish or increase a Put Equivalent Position (as defined in Rule 16a-1(h) under the Securities

Exchange Act of 1934, as amended (the “Exchange Act”)) or liquidate or decrease any Call Equivalent Position (as defined

in Rule 16a-1(b) under the Exchange Act), pledge, hypothecate or grant any security interest in, or in any other way transfer

or dispose of, any Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, in each case whether

now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition

(collectively, the “Lock-Up Securities”), (ii) make any demand for, or exercise any right with respect to the

registration of any of the Lock-Up Securities, or the filing of any registration statement, prospectus or prospectus supplement (or an

amendment or supplement thereto) in connection therewith, under the Securities Act of 1933, as amended (the “Securities Act”),

(iii) enter into any swap, hedge or any other agreement or any transaction that transfers, in whole or in part, the economic consequence

of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities,

in cash or otherwise, or (iv) publicly announce the intention to do any of the foregoing.

Notwithstanding

the foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities pursuant to clauses (i) through

(vi) below without the prior written consent of Canaccord, provided that (1) in the case of clauses (i) through

(v), prior to any such transfer, Canaccord receives a signed lock-up agreement, substantially in the form of this lock-up agreement, for

the balance of the Lock-Up Period from each donee, trustee, distributee or transferee, as the case may be, (2) in the case of clauses

(i) through (v), any such transfer shall not involve a disposition for value, (3) any required public filings or report

under Section 16 of the Exchange Act during the Lock-Up Period shall clearly indicate in the footnotes thereto that the such transfer

is being made pursuant to the circumstances described below, and (4) the undersigned does not otherwise voluntarily effect any public

filing or report regarding such transfers:

(i)            as

a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for bona fide

estate planning purposes; or

(ii)            to

any trust for the direct or indirect benefit of the undersigned or the immediate family (defined below) of the undersigned, or if

the undersigned is a trust, to a trustor, trustee or beneficiary of the trust or to the estate of a trustor, trustee, or beneficiary of

such trust; or

(iii)            to

any permitted transferee (defined below); or

(iv)            by

operation of law, such as pursuant to a qualified domestic order or in connection with a settlement related to the distribution of assets

in connection with the dissolution of marriage or civil union; or

(v)            by

will or intestate succession to the legal representative, heir, beneficiary or immediate family of the undersigned upon the death of the

undersigned; or

(vi) pursuant to a bona

fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Common Stock that has been

approved by the Company’s board of directors, which results in any person or group of persons becoming the beneficial owners (as

defined in Rules 13d-3 and 13d-5 of the Exchange Act) of more than 50% of the outstanding voting securities of the Company (or the

surviving entity); provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed,

the Common Stock shall remain subject to the provisions of this lock-up agreement.

The undersigned further agrees

that the foregoing provisions shall be equally applicable to any Securities the undersigned may purchase or otherwise receive in the Offering.

Furthermore, notwithstanding

the restrictions imposed by this lock-up agreement, the undersigned may, without the prior written consent of Canaccord: (a) exercise

an option to purchase shares of Common Stock granted under any stock incentive plan of the Company, which plan is described in the prospectus

supplement related to the Offering, provided that the underlying shares of Common Stock shall continue to be subject to the restrictions

on transfer set forth in this lock-up agreement and if the undersigned is required to file a report under Section 16 of the Exchange

Act reporting a reduction in beneficial ownership of shares of Common Stock during the Lock-Up Period, the undersigned shall clearly indicate

in the footnotes thereto the nature and conditions of such exercise or transfer and no other filing or public announcement shall be made

voluntarily during the Lock-Up Period in connection with such exercise or transfer; (b) establish a trading plan pursuant to Rule 10b5-1

under the Exchange Act for the transfer of shares of Common Stock, provided that, such plan does not provide for any transfers

of Common Stock during the Lock-Up Period; (c) transfer or dispose of shares of Common Stock purchased in the Offering from the underwriters

or on the open market following the Offering, provided that no filing under the Exchange Act reporting a reduction in beneficial

ownership of shares of Common Stock shall be voluntarily made during the Lock-Up Period; or (d) sell Lock-Up Securities for tax withholding

purposes in connection with the vesting of equity awards that are subject to a taxable event upon vesting of the Company’s securities,

it being understood that all shares of Common Stock received upon such vesting or transfer will remain subject to the restrictions of

this lock-up agreement during the Lock-Up Period, and provided that if the undersigned is required to file a report under the Exchange

Act reporting a reduction in beneficial ownership of the undersigned’s Common Stock during the Lock-Up Period related to such disposition,

the undersigned shall include a statement in such report to the effect that the filing relates to the satisfaction of tax withholding

obligations of the undersigned in connection with such vesting event and no other filing or public announcement shall be made voluntarily

during the Lock-Up Period in connection with such vesting or transfer.

The undersigned also agrees

and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of

the Lock-Up Securities except in compliance with the foregoing restrictions.

With respect to the Offering

only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of any shares

of Common Stock and/or any options or warrants or other rights to acquire Common Stock or any securities exchangeable or exercisable for

or convertible into Common Stock, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into

Common Stock, owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.

The undersigned confirms that

the undersigned has not, and has no knowledge that any immediate family member has, directly or indirectly, taken any action designed

to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company

to facilitate the sale of the Securities. The undersigned will not, and will cause any immediate family member not to take, directly or

indirectly, any such action.

As used herein, “permitted

transferee” shall mean (a) the members of the undersigned’s immediate family (for purposes of this lock-up agreement,

“immediate family” shall mean the spouse, domestic partner, lineal descendant (including adopted and step-children) and his

or her spouse, father, mother, the siblings of such person and his or her spouse, or any other person with whom the undersigned has a

relationship by blood, marriage or adoption not more remote than first cousin), (b) if the undersigned is a corporation, limited

liability company, partnership or other entity, its partners, shareholders, members of, or owners of similar equity interests in the undersigned

by way of distribution upon the liquidation and dissolution of the undersigned or (c) any affiliate of the undersigned.

The undersigned represents

and warrants that the undersigned has full power, capacity and authority to enter into this lock-up agreement. This lock-up agreement

is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.

This lock-up agreement shall

be governed by and construed in accordance with the laws of the State of New York.

Whether or not the Offering

actually occurs depends on a number of factors, including market conditions. Any Offering will only be made pursuant to an Underwriting

Agreement, the terms of which are subject to negotiation between the Company and Canaccord.

This lock-up agreement shall

automatically terminate, and the undersigned shall be released from its obligations hereunder, upon the earliest to occur, if any, of

(i) the Company advising Canaccord in writing, prior to the execution of the Underwriting Agreement, that it has determined not to

proceed with the Offering, (ii) the executed Underwriting Agreement being terminated prior to the closing of the Offering (other

than the provisions thereof that survive termination), and (iii) April 30, 2026, in the event that the Underwriting Agreement

has not been executed by such date.

[Signature Page Follows]

Very truly yours,

Name of Securityholder/Director/Officer

(Print exact name)

By:

Signature

If not signing in an individual capacity:

Name of Authorized Signatory (Print)

Title of Authorized Signatory (Print)

(indicate capacity of person signing if signing as custodian, trustee or on behalf of an entity)

ANNEX A

Form of Accompanying Warrant

WARRANT TO PURCHASE COMMON

STOCK

ANNOVIS BIO, INC.

Warrant Shares: [ ]

Issue Date: April 10, 2026

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”)

certifies that, for value received, [___] or its assigns (the “Holder”) is entitled, upon the terms and subject to

the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 10, 2026 (the “Initial

Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on that date that is five years and six months from

the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Annovis Bio, Inc.,

a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder,

the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 6. Definitions. Capitalized

terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the “Underwriting

Agreement”), dated April 9, 2026, by and between the Company and Canaccord Genuity LLC.

Section 7. Exercise.